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ABSTRACT 
There has been a continuing need for a better quantitative understanding of the 
gastrointestinal absorption of highly lipophilic drugs. With this aim in mind, the present 
study describes a physical model approach applicable to understanding the transport of 
lipophilic, ionizable drugs across a lipophilic membrane. In Chapter 3, model predictions 
were compared to experimental results of capric acid (HA) transport across a silicone 
polymer membrane in the presence and in the absence of 2-hydroxypropyl-P-cyclodextrin 
(HPB). Model predictions and experimental results were generally in agreement over the 
entire studied ranges of pH and HPB concentrations. In Chapter 4, the physical model 
approach was then applied to the in situ single pass perfusion system involving the rat 
ileum to obtain a more detailed understanding about cyclodextrin as an intestinal drug 
absorption enhancer through its role as a carrier. Model predictions were found to be 
generally in good agreement with experimental results. We also extended this model to 
account for the villus structure of the small intestine, resulting in equally good agreement. 
Both models demonstrated that HPB was able to reduce the capric acid concentration 
gradient across the aqueous boundary layer and increase the effective intestinal 
membrane surface area utilized for permeant absorption due to deeper penetration of the 
permeant into the villus crypts, accounting for the HPB-enhanced permeant flux. 
In an exploratory investigation (Chapter 5), the in situ single pass perfusion 
technique was then used to examine the ability of two well known chemical permeation 
enhancers of hydrophilic drug molecules, sodium caprate (HA) and sodium 
chenodeoxycholate (CDC), to enhance mannitol transport in the rat ileum in the presence 
and absence of different cyclodextrin carriers. Analysis of the experimental results with 
the villus model (VM) support the interpretation that an appropriate enhancer/carrier 
combination may 1) be able to increase the fraction of ileum surface area that is enhanced 
and, because of this, that 2) local toxicity effects of the enhancer might be avoided or 
reduced for any given mannitol permeability enhancement, while 3) at the same time 
provide increased enhancer duration of action. 
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CHAPTER 1 
INTRODUCTION 
This is an introduction and review of the literature relevant to oral drug 
absorption, with emphasis placed on details relating to the study of intestinal membrane 
permeability and the design of formulations intended to improve permeant 
bioavailability. Relevant intestinal anatomy, experimental methods for studying 
intestinal absorption, barriers to drug absorption, the BCS classification system, and 
common approaches for overcoming solubility and permeability limitations are reviewed 
herein. 
Oral dosage forms (i.e., tablets, capsules, suspensions, emulsions etc.) are the 
preferred method for administering drugs due to the safe, convenient, economical nature 
of oral dosing, and high patient compliance. Of the 50 most sold pharmaceutical products 
in the US and Europe, 42 are administered orally.1 Despite its popularity and numerous 
advantages over other dosing methods, oral dosing is not without significant limitations. 
Currently, many compounds and therapeutic chemical entities are not formulated for oral 
delivery due to poor drug solubility and/or low membrane permeability. Recent efforts to 
overcome solubility and permeability limitations have resulted in significant progress 
from the standpoint of practical formulation development; however, relatively little 
progress has been made from the standpoint of quantitatively understanding the 
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underlying mechanisms by which bioavailability enhancing formulations increase 
permeant flux. Therefore, an examination of appropriate models, both theoretically and 
experimentally, is necessary to advance the cause of more rational approaches to drug 
delivery formulation of low solubility and low permeability drug molecules. 
1.1 Anatomical and Physiological Features of the Gastrointestinal 
Tract Relevant to Oral Drug Delivery 
For oral dosage forms, the majority of drugs are absorbed primarily in the small 
intestine. The primary barrier to intestinal drug absorption is the innermost layer of the 
mucosa which consists of a 20 |im thick monolayer of simple columnar epithelium. Most 
permeants that traverse the epithelial monolayer are freely absorbed into the circulatory 
system via capillaries that reside just below the mucous epithelium. 
The small intestine contains several anatomical features which improve 
absorption by increasing the absorptive surface area. One feature that is present in 
humans, but largely absent in the rat is the plicae circulares, or folds of Kerckring, which 
increase the intestinal surface area by approximately a factor of three.2 The surface of the 
small intestine, including the folds of Kerckring, is covered with tiny fingerlike 
projections known as villi. These projections are present in both man and in the rat, and 
exist along the entire length of the small intestine, with the villus height, density, and 
diameter varying among species. In general, the villi are taller and thinner in the upper 
small intestine, becoming gradually shorter and wider towards the lower small intestine. 
The surface of the epithelial cells comprising the villi are covered with tiny hairlike 
structures called microvilli,. These microvilli, also present in both man and rat, further 
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amplify the absorptive surface area by 20-30 fold.2 Taken together, the folds of 
Kerckring, villi, and microvilli are reported to increase the surface area of the small 
intestine by up to 600 times compared with the surface area taken as a smooth, hollow, 
circular cylinder.2 
Although the small intestine has a surface area several hundred fold larger than its 
macroscopic surface area, this surface area is not used equally. It has been demonstrated 
that the effective surface area available for absorption is much less than the anatomical 
surface area of the mucosal membrane,3 and that the effective surface area utilized for 
absorption varies with the compound being absorbed.4"6 For highly permeable 
compounds, absorption occurs mainly at the tips of the villi, however low permeability 
compounds are able to penetrate more deeply into the villus crypts, taking greater 
advantage of the available surface area.4"6 
The pH of the gastrointestinal tract ranges from 1-2 in the stomach to 8-9 in the 
colon.2'7'8 The pH is controlled by enzymes and buffers secreted into the lumen at 
various locations in the gastrointestinal tract. This pH gradient down the intestinal tract 
influences the location at which weak acids and weak bases are most likely to be 
absorbed. 
1.2 Experimental Systems and Models for Determining 
the Absorption Rate of Drugs 
A large number and variety of experimental and computational methods are used 
to study, analyze, and predict passive intestinal absorption. These methods include 
theoretical models which predict absorption based solely on the properties of the 
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molecule of interest, artificial membrane experimental transport models, cell monolayer 
permeability models (i.e., Caco-2, PAMPA, etc.), excised tissue models (i.e., everted sac, 
Ussing chamber, etc.), in situ perfusion models, and in vivo models. Both animal and 
human models are available. No one method gives all the desired absorption rate 
information, and discrepancies both among and between experimental models is 
prevalent.9 Each method has its own advantages and disadvantages. Generally speaking, 
in vitro experiments provide opportunities for isolated examination of transport 
characteristics under simplified membrane transport conditions. These experiments do 
not, however, always correlate well with actual human results. In situ and in vivo 
experiments are generally more expensive, time consuming, and complex; however, the 
results may correlate more closely to actual human results. Smyth reviews in detail the 
methods of studying intestinal absorption.9 
1.3 Barriers to Drug Absorption 
1.3.1 The aqueous boundary layer 
The transport resistance due to the aqueous boundary layer (ABL) is well 
established, and should be considered in the analysis of transport across biological 
membranes.10"13 The effective thickness of the ABL is flow-rate dependent and the 
contribution of the ABL to the overall transport resistance is often dependent upon many 
parameters. Komiya et al.14 and Tsutsumi et al. used intestinal perfusion techniques in 
rat jejunum and ileum, respectively, to demonstrate that the overall transport rate of a 
series of steroids increased initially with increasing lipophilicity, reaching a plateau for 
the more lipophilic steroids. This plateau was shown to be due to the ABL, with the 
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transport of the highly lipophilic steroids being entirely ABL controlled. Yuasa et al.16 
used a single pass perfusion technique with the rat jejunum to demonstrate that the 
effective ABL thickness was greater in anesthetized rats (785 |Lim) than in un-
anesthetized rats (319 |im) for a 0.16 ml/min flow rate. They also demonstrated that even 
at higher flow rates (2.95 ml/min) the ABL still accounted for 85% of the total transport 
resistance of D-glucose. This demonstrated that although conscious animals have 
increased villus motility and decreased ABL thickness as compared to anesthetized 
animals, the ABL cannot be neglected. 
1.3.2 The epithelial membrane 
1.3.2.1 Transcellular transport 
Transcellular simple diffusion is the preferred route of transport for lipophilic 
molecules and for very small molecules in general.17 Some very small hydrophilic 
molecules (e.g., H2O) are thought to diffuse freely through transcellular pores, whereas 
larger lipophilic molecules partition into the lipid bilayer and are thought to diffuse 
laterally along the plasma membrane toward the basal membrane.19 For lipophilic 
molecules, the transcellular membrane permeability coefficient has been shown to be 
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related to permeant lipophilicity. 
1.3.2.2 Paracellular transport 
Epithelial cells making up the intestinal transport barrier are joined to each other 
at intercellular junctions by a junctional complex. Adherence points include gap 
junctions, spot desmosomes, intermediate junctions, and zonula occludens (also known as 
6 
tight junctions).17 These junctions hold the cells making up the epithelial monolayer 
together. The tight junction is the apical-most junction and is generally considered the 
rate limiting junction with regards to the diffusion of molecules through the paracellular 
pathway. The tight junction also forms a "fence" between the apical and lateral plasma 
membrane domains, which prevents the random diffusion of membrane lipids and 
proteins between these two compartments which maintains cell surface polarity and 
91 
prevents lipid molecules from diffusing between epithelial cells. The pores formed 
between the cells are the paracellular transport pathway, and the pore diameters are 
regulated by the tight junctions. This pore pathway is thought to be the principle 
transport pathway for molecules too polar to partition into the phospholipid bilayer. Any 
molecule small enough to diffuse through the aqueous pore formed by the tight junction 
can be transported via the paracellular pathway. Several transmembrane proteins have 
been identified as associating with tight junctions, and some chemical permeation 
enhancers are thought to act either directly or indirectly on the function of these proteins 
to increase the tight junction pore size. Although relatively little is known about how 
these proteins regulate the tight junction pore size and interact with chemical permeation 
99 
enhancers, there has been a significant amount of work done to identify mechanisms 
and interactions involved in tight junction modulation. 
1.4 The Biopharmaceutical Classification System (BCS) 
An increasing number of biologically active compounds discovered using high 
throughput screening have low inherent oral bioavailability because they are either large 
and polar, resulting in low permeability, or they are very lipophilic, resulting in low 
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aqueous solubility. Potential candidates for oral drug delivery are classified based on 
their solubility and permeability characteristics. Table 1.1 presents a recommended 
method accepted by the FDA for classifying potential permeant molecules into four 
categories based on solubility and permeability.27 
This classification of potential drug candidates identifies the rate limiting step(s) for 
oral drug delivery. Poor solubility and/or low permeability characteristics may cause 
otherwise active therapeutic agents to be dropped in the early stages of product 
development due to the difficulty of developing a formulation with adequate 
bioavailability. 
1.5 Approaches for Overcoming Solubility and Permeability Limitations 
1.5.1 Drug carriers for improving solubility 
Many biologically active compounds have inadequate bioavailability for 
successful oral dosing because of poor membrane permeability, water solubility, and/or 
stability characteristics. One category of drug molecules that has been receiving much 
attention recently is that class of compounds which are both highly lipophilic and poorly 
water soluble (BCS classification class II).28 For drug molecules in this category, an 
approach often taken to improve bioavailability is the inclusion of a solubilizing agent in 
the formulation to increase the drug solubility and to effect a greater maximum flux of 
drug into the blood stream. 
In recent years, cyclodextrins (CD) have received extensive attention as 
solubilizing agents in aqueous media because of their ability to form inclusion complexes 
with lipophilic drugs. Specifically, 2-hydroxypropyl-P-cyclodextrin (HPB) has been 
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studied as a potential excipient in drug formulations because of its ability to improve the 
drug delivery characteristics for a large number of molecules.37"46 
One concern about using cyclodextrins in oral formulations is that of safety. As 
with any potential excipient, questions arise concerning possible adverse side effects. 
While un-substituted cyclodextrins and cyclodextrins with lipophilic substitutions have 
been shown to cause damage to erythrocytes and biological membranes,47'48 the safety of 
HPB in oral formulations has been well documented.49"54 It has been demonstrated that 
HPB concentrations up to 100 mM do not extract lipids from biological membranes or 
otherwise disrupt the integrity of epithelial cells.55"57 In addition to HPB being well 
tolerated, it is highly soluble and not significantly absorbed in the gastrointestinal 
tract.58'59 These characteristics make HPB a good candidate as a potential solubilizing 
agent in oral dosage forms. Accordingly, the FDA has included HPB in its list of 
Inactive Pharmaceutical Ingredients.37 In fact, HPB has already been used in approved 
and marketed drug formulations in Europe, Japan, and the United States, with several 
more formulations in clinical trials.60 
1.5.2 Chemical enhancers for improvin2 membrane permeability 
Effective gastrointestinal absorption of highly polar molecules is frequently 
limited by poor intestinal permeability. Because high solubility low permeability (BCS 
class III) molecules generally have low bioavailability, oral dosing formulations are not 
only inefficient, but generally have much higher inter- and intra-subject variability.61"63 
Recent efforts to improve intestinal permeability, and therefore bioavailability, of BCS 
class III compounds has included, among other approaches, the use of membrane 
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penetration-enhancing excipients. Compounds that have been studied for their membrane 
penetration-enhancing effects include ionic and non-ionic surfactants,64"73 bile salts, 
fatty acids,85"93 glycerides,94"100 and others.64"67,101"103 Intestinal membrane penetration 
enhancers consist of a wide range of molecules with a variety of molecular structures and 
mechanisms of action. Aungst et al.104 believe that the three most important issues that 
need to be considered for evaluating absorption enhancers are: (1) how effective the 
absorption enhancer is for the drug of interest, (2) the potential to cause toxicity, and (3) 
the mechanisms by which absorption is enhanced. Frequently, the toxicity of the 
enhancers themselves is the limiting factor in successful application of the permeability 
enhancer.66'105'106 Additionally, enhancers are generally rapidly absorbed, and have a 
short half-life in the intestinal tract, which limits the duration of action of the enhancer. 
An ideal enhancer formulation would minimize enhancer toxicity and increase the 
duration of action. An approach that could incorporate these characteristics into an 
enhancer formulation would certainly increase the likelihood that a formulation could 
become a marketable product. 
11 
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CHAPTER 2 
STATEMENT OF THE PROBLEM 
Efforts to improve gastrointestinal drug delivery have been on going for many 
years and the use of carrier molecules to improve solubility and transport of lipophilic 
drugs has become increasingly popular in recent decades. Although there is qualitative 
understanding of how cyclodextrin carriers improve drug transport, the complex interplay 
of the parameters involved is not well understood. The purpose of the present research 
project has been to quantify the effects of cyclodextrin carriers on the intestinal 
absorption of highly lipophilic (BCS class II) compounds and to examine the use of 
cyclodextrin carriers for more effectively presenting permeation enhancers to the surface 
of the ileum for the intestinal absorption enhancement of polar (i.e., BCS Class III) 
compounds. This will be accomplished through the following specific aims. 
1. Develop a physical model that predicts the transport of a highly lipophilic weak acid 
molecule (the permeant) across a lipophilic membrane from aqueous buffered 
solutions in the presence of a cyclodextrin carrier. This model will account for the 
permeant and carrier concentrations and the following parameters: solution pH, 
permeant pKa, aqueous boundary layer (ABL) thickness, permeant-carrier binding 
constant(s), intrinsic membrane permeability coefficient, and diffusion coefficient(s). 
These parameters will be quantified using independent methods where feasible. 
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2. Experimentally determine the transport rate of a highly lipophilic weak acid molecule 
(capric acid) across a silicone polymer membrane in the presence of a hydroxypropyl-
P-cyclodextrin (HPB) carrier, choosing experimental conditions that cover the range 
from ABL-controlled to membrane-controlled transport. The experimental results 
will be compared to those predicted from the model. 
3. Experimentally determine the transport rate of a highly lipophilic weak acid molecule 
(capric acid) across the rat ileal membrane in the presence of a cyclodextrin carrier 
using the in situ single pass perfusion technique. The experimental results will be 
compared to those predicted from the model developed in vitro with the silicone 
polymer membrane. The model will then be modified to account for the villus 
structure of the rat ileum, and the experimental results will be analyzed using the 
villus model (VM). 
4. Demonstrate the permeability enhancement in the rat ileum using solutions containing 
an intestinal membrane permeation enhancer (capric acid or chenodeoxycholic acid) 
in the presence and absence of a cyclodextrin carrier. The effect of the cyclodextrin 
carrier on the presentation of the permeation enhancer to the surface and its 
accompanying membrane enhancement will be experimentally determined and 
interpreted using the physical model predictions. 
CHAPTER 3 
TRANSPORT OF A LIPOPHILIC IONIZABLE PERMEANT (CAPRIC ACID) 
ACROSS A LIPOPHILIC MEMBRANE (SILICONE POLYMER 
MEMBRANE) FROM AQUEOUS BUFFERED SOLUTIONS 
IN THE PRESENCE OF HYDROXYPROPYL-(3-
CYCLODEXTRIN 
3.1 Introduction 
Many biologically active compounds have inadequate bioavailability for 
successful oral dosing because of poor biological membrane permeability, water 
solubility, and/or stability characteristics. One category of drug molecules that has been 
receiving much attention recently is that class of compounds which are both highly 
lipophilic and poorly water soluble (BCS classification class II).1 For drug molecules in 
this category, an approach often taken to improve bioavailability is the inclusion of a 
solubilizing agent in the formulation to increase the drug solubility and to effect a greater 
maximum flux of drug into the blood stream.2"7 
In recent years, cyclodextrins have received extensive attention as solubilizing 
agents in aqueous media because of their ability to form inclusion complexes with 
lipophilic drug molecules. Of particular interest, 2-hydroxypropyl-P-cyclodextrin (HPB) 
has been studied as a potential excipient in drug formulations because of its ability to 
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improve the drag delivery characteristics for a large number of molecules. " HPB is 
highly water soluble, well tolerated at moderate doses, is not significantly absorbed in the 
gastrointestinal tract, and is cited in the FDA's list of Inactive Pharmaceutical 
Ingredients,8 making it a good example of an excipient for oral drug delivery 
formulations of poor solubility, high permeability drugs. 
While there has been much progress from the standpoint of practical 
formulation development involving inclusion complexes, there has been relatively little 
progress from the standpoint of the quantitative mechanistic understanding of the 
interplay of certain key variables, and therefore it should be desirable to examine 
appropriate models both theoretically and experimentally that may advance the cause of 
more rational approaches in the area of formulation development of orally delivered, high 
lipophilicity/low solubility drug molecules. The present study builds upon earlier model 
studies done by Amidon et al.2 who examined transport of progesterone across a silicone 
polymer membrane and the transport-enhancing effects of polysorbate-80 micelles in the 
aqueous medium. In the current study, a physical model approach is presented for the 
transport of a lipophilic weak acid molecule across a lipophilic biological membrane in 
the presence of a carrier in the aqueous phase with the particular purpose of obtaining a 
better understanding of the interplay of key variables involved. In the present case, the 
model situation is that where capric acid (HA) is the high lipophilicity weak acid 
molecule (playing the role of surrogate for a drug molecule), and its transport across a 
silicone polymer membrane (the surrogate for a lipophilic biological membrane) 
positioned between two aqueous compartments in the presence of the carrier HPB in the 
aqueous phase. The expected high silicone polymer membrane/water partition 
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coefficient and the expected high diffusivity of the capric acid molecule in the silicone 
polymer membrane17 is expected to allow for a significant influence of the aqueous 
boundary layer (ABL) on the overall capric acid transport rate. The model takes into 
account the capric acid and HPB concentrations, solution pH, aqueous boundary layer 
thickness, the capric acid dissociation constant, the capric acid/silicone membrane 
intrinsic permeability coefficient, the capric acid/HPB and the caprate ion/HPB binding 
constants, and the diffusion coefficients of all four species. 
3.2 The Model and Equations Used in 
the Analysis of Experimental Data 
Here we describe the general model with a principal aim of obtaining from it the 
equations for the interpretation of the experiments conducted in the present study. The 
model also serves as the template for the design of experimental strategies aimed at the 
quantitation or the confirmation thereof of species-specific diffusion coefficients, the 
capric acid dissociation constant, the binding constants for the two complexes, and the 
capric acid permeability coefficient of the ABL and that of the silicone membrane. 
In an aqueous solution containing capric acid and HPB in equilibrium, the total 
caprate concentration (CT) in the bulk donor solution, in the ABL, or in the solution at the 
membrane-solution interface, as the case may be, is 
cT=c
u+cr+c*u+c*- (3.i) 
where C denotes concentration and the superscripts u, - , *u, and *- represent the capric 
acid molecule (HA), caprate ion (A~), capric acid-HPB complex (HA»HPB) and caprate 
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ion-HPB complex (A~»HPB) species, respectively. Since the concentration of each 
species is equal to the product of the molar fraction (F) of each species and CT, 
C T =(F U +F-+F* U +F*-)C T (3.2) 
where these fractions are related to the HPB concentration, pH, CT, the acid dissociation 
constant (Ka) of capric acid, and the two binding constants, Ku (for HA*HPB ) and K~ 
(for A~»HPB). The steady-state flux across the ABL (JABL) from the stirred bulk donor 
solution to the membrane surface is the sum of the fluxes of all the caprate species across 
the ABL: 
•* ABL 
((DUFU + D~F~ + D*UF*U + D*F*_) ^ 
hABL 
^ T , D ^-"T.S/ \?'->) 
where the D's are the diffusion coefficients, hABL is the ABL thickness, and CT,D and CT,S 
represent the total caprate concentration in the donor bulk solution and at the solution-
membrane interface, respectively. The effective total caprate diffusion coefficient in the 
aqueous phase (Deff) is: 
Deff = DuFu + D - F - + D*uF.u + D*-F*- ( 3 4 ) 
The effective total caprate permeability coefficient for the ABL (P^ L ) is then: 
Deff 
P I B L = ^ - (3-5) 
nABL 
It follows then that, 
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• 'ABL = "ABL '^T .D — *-"T,S) W - ° / 
Taken together, Eqs 3.4 and 3.5 tacitly assume that there exists rapid chemical 
equilibria everywhere in the ABL and that there is no significant convective contribution 
to caprate transport in the ABL. When only capric acid molecules are able to partition at 
the solution/membrane interface and diffuse across the membrane into the receiver sink, 
the capric acid membrane flux (Jm) 
Jm=PmCT , s (3.7) 
where the effective capric acid membrane permeability coefficient (Pm) is the product of 
the intrinsic membrane permeability coefficient (Pi) and the fraction of the free capric 
acid species (Fu): 
Pm=P iFu (3.8) 
The intrinsic permeability coefficient is given by 
kn iDm 
p
 = ^ ^ _ m ( 3 9 ) 
where kPij is the intrinsic capric acid/silicone polymer partition coefficient, Dm is the 
diffusion coefficient of capric acid molecule in the silicone polymer membrane, and hm is 
the membrane thickness. The continuity of the flow of mass at steady-state is given by 
J A B L = J m = J (3-10) 
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where J is the overall flux across the system. With Eqs 3.10, 3.6 and 3.7, the membrane 





peff + P F U 
(3.11) 






from which it is apparent that the total permeability coefficient (PT) encompassing both 
the ABL and the membrane transport barriers is: 
PT = 
1 3eff ABL 
1 1 
+ -,eff pen p pu 






The mathematical form of the right-most side of Eq 3.13 permits one to readily assess the 
extent to which the overall transport is ABL-controlled and membrane-controlled. The 
permeability coefficient (Pj) in Eq 3.13 is predictable when the HPB concentration, pH, 
CT,D> capric acid Ka, KT, Ku, Deff, IUBL, and Pj are known. It is understood that the present 
physical model does not consider pH gradients within the ABL. Consequently, 
sufficiently high buffer capacity to maintain a constant pH everywhere is presumed. 
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Additionally, Deff (see Eqs. 3.3 and 3.4) would be constant across the entire ABL for a 
given set of experimental conditions strictly only when the uncomplexed HPB, i.e., the 
free HPB (HPBf) concentration is much greater than the concentrations of the complexes. 
This condition is met for all experiments in the present study. For the general case in 
which the HPB concentration may not be always much greater than the concentrations of 
the complexes, the finite element numerical method discussed in Chapter 4 may be 
employed to calculate the ABL-location dependent Deff values for each experimental 
situation. 
3.3 Strategy 
The present work was expected to be particularly helpful in interpreting the 
results of the capric acid rat intestinal absorption experiments which have been 
concurrently conducted in our laboratory and the results for which are presented in 
Chapter 4. In the present study, the physical model is developed and tested with a 
silicone polymer membrane mounted between two aqueous phases in a side-by-side 
diffusion cell system. Silicone membranes have been commonly used as in vitro 
surrogates in the attempt to mimic characteristics of biological membranes.18'19 Key 
parameters entering into the equations for the physical model are to be determined 
experimentally by independent (or essentially independent) methods. The capric acid Ka 
and the capric acid/HPB binding constants (Ku and K~) are determined by equilibrium 
silicone polymer membrane partitioning experiments and/or by selected silicone 
membrane capric acid transport studies; the free and the complexed caprate species 
diffusion coefficients are determined from fritted glass disk diffusion experiments; the 
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intrinsic silicone membrane capric acid permeability coefficient and the effective ABL 
thicknesses are determined from best-fit analyses of selected data from silicone 
membrane/capric acid transport experiments over a range of conditions particularly 
sensitive to these parameters. 
The buffers used in the present study are all at an ionic strength of 0.37 M as this 
is the ionic strength of the media employed in the rat intestinal perfusion experiments. ' 
For the same reason, all experiments involved in the determination of the model 
parameters as well as all of the main transport experiments were conducted in appropriate 
media at the ionic strength of 0.37 M. The buffer capacities, ranging from 9.5xl0"3 to 6 x 
10"3 M for 0.01 M citrate buffers, pH 3.0 to 6.0, and 3.1xl0"2 M for 0.057 M phosphate 
buffers, pH 7.0 and 7.4, were all sufficiently large so that the additions of 5xl0"5 M cold 
capric acid would have had inconsequential effects (ApH < 0.005) on the buffer pH. 
Therefore, no significant pH gradients across the ABL were anticipated. 
The main capric acid transport experiments of this study are conducted with a) the 
silicone membrane alone (SM) in the diffusion chamber or b) the silicone membrane plus 
six Millipore membranes assembled together and held closely against the silicone 
membrane on the donor compartment side (SM-MM). The latter is essentially a 
composite membrane possessing a significantly greater effective ABL thickness than in 
the SM case, this to more closely approximate the magnitude of the effective ABL 
thickness of the rat intestinal tract. Although the capric acid-to-HPB concentration ratios 
in the present experiments were always very much less than unity (i.e., HPB 
concentration » CT), the ratios were varied in conjunction with pH to provide a wide 
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range of conditions that not only enabled the validation/quantitation of species-dependent 
physicochemical parameters, but also more effectively demonstrated the quantitative 
interplay of multiple factors. The receiver compartment is always maintained at pH 9.5 
with adequate buffer capacity for the purpose of efficient extraction of capric acid from 
the membrane and the elimination of any significant ABL resistance in the receiver 
chamber. All experiments are performed at 30°C as this has been the mean temperature 
of the perfusate in the in situ rat intestinal perfusion experiments. 
While being a surrogate for the weak acid lipophilic drug molecule in the present 
study, capric acid has been commonly investigated as a possible intestinal drug 
absorption enhancer for low permeability, highly polar drug molecules.22"24 Therefore, a 
major independent reason for using capric acid and HPB in the present study is that we 
have been investigating this combination in exploratory in situ studies to determine the 
modulating influence of HPB on the biomembrane transport enhancement of highly polar 
compounds in the rat ileum by capric acid. The results of this exploratory investigation 
are discussed in Chapter 5. 
3.4 Experimental 
3.4.1 Chemicals and reagents 
Capric acid and caprylic acid were purchased from Sigma-Aldrich Company (St. 
Louis, MO). [14C]Urea, [14C]mannitol, [14C]sucrose, [14C]capric acid, and [14C]caprylic 
acid of radiochemical purity >97% were obtained from Moravek Biopharmaceuticals 
(Brea, CA). Hydroxypropyl-P-cyclodextrin (HPB) was a generous gift from Roquette 
America (Keokuk, IA). Trifluoroacetic acid was obtained from Acros (New Jersey, 
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USA). Dimethyl silicone polymer membranes (100 |im thick, SSP-M823) obtained from 
Specialty Silicone Products (Ballston Spa, NY) were cut into 20 mm diameter disks. 
Millipore filter membranes (0.22 \im) were obtained from Millipore Corp. (Bedford, 
MA). Borate buffer pH 9.5 (Item No. 2307) was obtained from GFS Chemicals 
(Columbus, OH). All other chemicals and reagents were obtained from Sigma-Aldrich 
Company (St. Louis, MO). 
3.4.2 Methods 
3.4.2.1 Determination of the capric acid pK^ (at ionic strength=0.37) 
and the intrinsic capric acid aqueous-silicone polymer partition 
coefficient, k^, by the silicone membrane partitioning method 
Citrate buffers (10 mM) at pH 3.0, 3.5, 4.0, 4.5, 4.7, 5.0, and 5.5, and phosphate 
buffers (57 mM) at pH 6.0 and 6.5, all with 0.05 mM cold sodium caprate and 0.02% 
sodium azide, were adjusted to 0.37 ionic strength using sodium chloride. All pH 
measurements were conducted with an Orion 320 pH meter manufactured by Thermo 
Electron Corporation calibrated with pH 4.0, 7.0, and/or 10.0 Fisher Scientific standard 
pH buffers. A trace amount of [C14]capric acid (0.01-0.1 |iCi/ml) was added to each 
buffer solution. A 5 ml aliquot of each solution was added to a 20 ml scintillation vial 
containing a preweighted silicone polymer membrane disk and equilibrated at 30 °C in a 
shaking water bath for 48, 72, or 96 hours. After equilibration, a 1ml sample of the 
equilibrated solution was pipetted into 10 ml of scintillation cocktail in a scintillation 
vial; the silicone disk was then removed and rinsed for 10 seconds in distilled water 
adjusted to pH 3.0 using 1 molar hydrochloric acid. The silicone disk was then dried 
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with a paper towel and transferred into a 20 ml scintillation vial. Then 200 |il of 100% 
trifluoroacetic acid was added into the vial and the disk was allowed to completely 
dissolve (10 min); then 10 ml of scintillation cocktail was added to this solution. Both 
the equilibrated aqueous solution sample and the dissolved silicone disk sample were 
assayed using the Packard TriCarb 1900TR liquid scintillation counter. The apparent 
partition coefficient, kp>app, was calculated by 
k n a n n = ^ : L (3.14) 
where Cs,p and Caq are the capric acid concentration (mole/cc) in the silicone polymer and 
total caprate concentration in the aqueous phase (mole/cc), respectively. The intrinsic 
partition coefficient (kp?j) and pKa were then simultaneously determined by best-fitting 
the data to Eq 3.15. A good fit of all the data to Eq 3.15 with the two best-fit parameters 
(kp,i and pKa) would also directly suggest that only the unionized capric acid molecule 
may partition into the silicone membrane polymer. 
kni v
 = P'1 n 15^ 
P'app
 1 + 1Q(pH-pKa) yj.uj 
Experiments were performed in triplicate for each pH condition. This procedure was 
repeated using caprylic acid at an ionic strength of 0.1 to validate the method by 
comparing experimentally determined caprylic acid Ka values to literature values. 
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3.4.2.2 HA+HPB and A~»HPB binding constants, Ku and K~ 
The model assumes that HPB forms only 1:1 complexes with both the neutral and 
the anionic capric acid species; this assumption is consistent with the diffusion coefficient 
data (to be discussed later) and with results of transport experiments with 500 molecular 
weight cut-off membranes at various concentrations of HPB and total caprate (data not 
shown). The model also assumes that uncomplexed HPB (i.e., HPBf in Eq 3.16), exists 
only as monomers. This is considered to be a reasonable assumption by noting, for 
example, that the water solubility of corticosterone (a steroid for which its interaction 
with HPB in aqueous solutions is best explained by the formation of a one-to-one 
complex) increases linearly with increasing free HPB concentration over the HPB 
concentration range of the present study.14 
The following equation was used to determine Ku 
K u = (3.16) 
Cu[HPBf] 
where [HPBf] denotes the free HPB concentration. Cu and C*u were determined from 
FU=C7CT (3.17) 
F*U=C*7CT (3.18) 
Because, as will be seen, the partitioning of the caprate ion into the silicone polymer 
membrane is negligible compared to the unionized capric acid molecule, Fu can be 
determined from 
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p u = _p ; app - (3.19) 
kp,i 
kp.app was experimentally determined using the same method as in Section 3.4.2.1 at pH 
3.0 (essentially 100% unionized capric acid), ionic strength = 0.37, and 30°C in the 
presence of 0, 0.33, 1, and 3 mM HPB. How kp?i for capric acid was determined 
independently has already been discussed Section 3.4.2.1. At low pH, F u could be 
determined from Fu because Fu + F u ~ 1 (At pH 3.0, the uncertainty in F u because of this 
approximation will be seen to be less than 3% over the HPB concentration range of the 
present study). 
In the case of KT, where 
K_ = (3.20) 
CT[HPBf] 
the apparent partition coefficient (kp)app) of capric acid for silicone membrane at high pH 
in the presence of HPB was too low to permit an accurate determination of K~. 
Therefore, K~ was determined from a least squares best-fit of select data at pH 7.4 and 
pH 7.0 on capric acid transport across one silicone membrane in the presence of varying 
concentrations of HPB in the donor chamber at 30°C. 
3.4.2.3 Determination of aqueous diffusion coefficients 
Diffusion cell transport experiments were designed for determining the diffusion 
coefficients of the four species- the capric acid molecule (HA), the caprate ion (A-), 
HA«HPB, and A~»HPB. The experiments were conducted at 30°C with various HPB 
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concentrations in a pH 7.4 buffer and in a pH 3.0 buffer. The dominant species were 
expected to be the caprate ion and A~*HPB at pH 7.4 and the capric acid species and 
HA»HPB at pH 3.0. The pH 7.4 buffer was comprised of 57 mM NaH2P04H20 and 79 
mM Na2SC>4. The low pH buffer was 10 mM citric acid adjusted to pH 3.0 with 10 M 
NaOH. For both buffers, the ionic strength was adjusted to 0.37 with reagent grade 
sodium chloride. The pH 7.4 buffer was also used in the single pass rat ileum perfusion 
studies (Chapter 4). The diffusion cell experiments employed a method described by 
Peck et al. Briefly, a glass tube containing an embedded, medium fritted glass disk 
(LG-7160-140) (thickness of 2.5 mm, nominal pore size of 10-15 urn and an inside 
diameter of 10 mm) was obtained from Wilmad-Labglass (Buena, NJ) and permanently 
fused into a side-by-side diffusion cell system at the University of Utah glass shop. 
These cells were constructed to have ~3 ml donor and receiver chambers and a 
diffusional area (A) of 0.78 cm2. Teflon-coated magnetic stir bars (2mm x 6mm) 
provided continuous stirring in the donor and receiver chambers during a transport 
experiment, and the temperature was maintained at 30°C by a circulating water bath. 
Removable stopcocks were used to prevent convective flow between the two chambers at 
the start of and during the transport experiment. 
The experiment was initiated by filling the donor compartment with the donor 
solution of a solute of interest and then sealing it off using a stopcock. The receiver 
compartment was filled with 2.5 ml of the receiver solution and left open for sampling. 
In the capric acid diffusion cell experiments, the composition of the donor and receiver 
was always the same except for trace levels of [14C]capric acid in the donor solution. A 
36 
lml sample of the receiver solution was taken with replacement of fresh receiver solution 
at predetermined time points. Two 20ui donor solution samples were taken at the 
beginning and the end of the experiment to determine initial and final donor solute 
concentration. Samples were mixed with 10 ml Ultima Gold scintillation cocktail, 
assayed by scintillation counting, and the fritted disk permeability coefficient was 
calculated from 
P T = ^ - ^ (3.21) 
T
 ACD dt 
where Co is the solute concentration in the donor compartment and — is the steady-
dt 
state slope of the cumulative amount of solute transported vs. time plot. CD was 
determined from the average of the 20 jjl donor samples (CD changed less than 5% over 
the course of a typical experiment). The aqueous diffusion coefficient is then calculated 
by 
D X ^ D R (3-22) 
"T,R 
where the subscripts X and R denote the solute of interest and the reference solute, 
respectively. [14C]Sucrose was used as the reference solute. The experimental diffusion 
coefficients for the caprate ion and the capric acid species were determined at pH 7.4 and 
pH 3.0, respectively, using the buffers and range of conditions described above. The 
experimental diffusion coefficients for the complexes, A~»HPB and HA«HPB, were 
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determined over a range of HPB concentrations in the pH 7.4 phosphate buffer and at 30 
mM HPB in the pH 3.0 citrate buffer, respectively. The diffusion coefficients for 
[14C]urea and [14C]mannitol were also determined at pH 3.0 and/or 7.4 (ionic strength = 
0.37) for comparisons with temperature- and ionic strength-corrected literature values. 
3.4.2.4 Viscosity measurements 
A size 25 kinematic viscometer (Technical Glass Products Inc.,Dover, NJ) was 
used to obtain kinematic viscosity values for the various solutions described in Section 
3.4.2.3. All measurements were done in triplicate. 
3.4.2.5 Capric acid transport experiments: silicone membrane alone (SM) 
or silicone membrane plus six millipore membranes (SM-MM) 
A 20 mm diameter, 100 urn thick silicone membrane alone or together with six 
Millipore membranes was mounted in a side-by-side diffusion cell having a surface area 
(A) of 0.78 cm2. The donor and receiver solution volumes were 2 ml each. The donor 
and receiver solutions were stirred at approximately 450 rpm using a magnetic stir bar 
(2mmx6mm), and the experiment was maintained at 30°C by a circulating water bath. 
The buffers for the donor solutions were citrate (for pH 3.0-5.5) or phosphate (for pH 6.0-
7.4) described in Section 3.4.2.3, with the pH adjusted using 10 M NaOH. The receiver 
solution buffer was always the pH 9.5 borate buffer, this effectively eliminating any 
aqueous boundary layer resistance for capric acid transport in the receiver chamber side 
of the silicone membrane. The capric acid transport experiments were conducted with a 
trace concentration (0.04-0.2 p,Ci/ml) of [14C]capric acid present in the donor chamber 
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and with the HPB concentration (0-30 mM) and 0.05 mM cold capric acid and 0.02% 
sodium azide in both the donor and receiver chambers. 
The transport experiment was initiated by loading the donor and receiver 
chambers with 2ml of donor and receiver solution, respectively. One-half (i.e., 1ml) of 
the donor solution and all of the receiver solution were replaced at predetermined time 
points to allow [14C]capric acid transport to reach steady state. After steady-state was 
attained, 1ml receiver samples were taken with replacement and 20iJ.l donor samples were 
taken at predetermined time points. The sampling time points were chosen such that the 
receiver chamber had gained sufficient concentration in 1ml buffer for assay, and the 
donor capric acid concentration remained within 5% of the initial concentration over the 
duration of the experiment. After taking a set of samples, 1ml of the donor solution was 
replaced with fresh donor solution, the receiver chamber solution was removed as 
completely as possible by pipette and then rinsed and replenished with 2ml of fresh 
receiver solution, and another transport run was conducted. This process was repeated 
until four sets of samples were taken for a given condition. The samples were mixed 
with 10 ml scintillation cocktail and analyzed by scintillation counting. The experimental 
total permeability coefficient (Pj) was calculated using the same Eq 3.21 used in the 
diffusion coefficient determination. 
3.4.2.6 Six millipore membranes (MM) only transport experiments 
Six Millipore membranes were wetted with buffer solution under vacuum to 
remove any air bubbles, assembled and mounted as a composite membrane in the same 
side-by-side diffusion cell used for silicone transport studies. The donor and receiver 
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solutions consisted of either pH 3.0 citrate buffer or pH 7.4 phosphate buffer and either 0 
or 30 mM HPB. These buffer solutions were prepared in the same manner as described 
in Section 3.4.2.3. The donor solution also included trace (0.01-0.1 wO/ml) [C14]capric 
acid or [C14]mannitol. The experiments were performed in a manner similar to that 
described in Section 3.4.2.4 and the Px values calculated. 
3.5 Results 
3.5.1 Key parameters associated with the capric 
acid transport across the silicone membrane 
The independently determined parameters that are involved in the physical model 
calculations of the transport of capric acid across silicone membrane in the presence of 
HPB are summarized in Table 3.1. The details are discussed in the following sections. 
3.5.1.1 Capric acid pKa and the intrinsic capric acid 
aqueous-silicone polymer partition coefficient, k^ 
The capric acid apparent partition coefficients (kp>app) calculated from the 
experimental data using Eq 3.14 were found to be independent of time from 48-96 hours, 
verifying that capric acid was in equilibrium with the silicone membrane within 48 hours. 
Fig 3.1 shows the experimentally determined kP;app. The solid line represents the least-
squares best-fit of the experimental kp,app to Eq 3.15. Briefly, the experimental kp>app at 
pH 3.0 was used as the initial guess for kp,i, and the least-squares best-fit pKa was 
determined using the pH 3.5-5.5 experimental data according to Eq 3.15. This pKa was 

































































































































































































































































































































































































Fig 3.1 The apparent partition coefficient ( kp,app) for capric acid 
partitioning into silicone polymer membrane in 10 mM citrate buffers 
and 57 mM phosphate buffers ranging from pH 3.0 to pH 6.5 (ionic 
strength = 0.37). The curve represents best-fitting Eq 3.15 to the 
experimental kP(apP data and the best-fit values of pKa and kP)i were 4.53 
(± 0.03) and 315 (±14) , respectively. The apparent partition 
coefficients for capric acid at pH 3.0 in the presence of 0.33, 1, and 3 
mM hydroxypropyl-P-cyclodextrin (HPB) are also shown. 
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new kp>i was then, in turn, used in Eq 3.15 to find the least-squares best-fit pKa to the pH 
3.5-5.5 data. This process was repeated until successive iterations resulted in no further 
changes in the kp,i or the pKa. 
The results of the best-fitting procedure yielded a kPij value of 315 (± 14) and a 
pKa value of 4.53 (± 0.03). Fig 3.1 demonstrates the good fit of the data to Eq 3.15 over 
the entire range of the kPjapp values. In order to increase the level of confidence in the pKa 
determination method (silicone partitioning), the pKa of caprylic acid was also 
determined at 25 °C and 0.1 ionic strength. This experimentally determined pKa value of 
caprylic acid was then compared to literature values that were corrected for ionic 
strength using the extended Debye-Huckel equation and Kielland's ion size parameter of 
6 for the caprylic acid ion.27'28 The experimental pKa of caprylic acid at 0.1 ionic 
strength was determined to be 4.69 (±0.03) with a kp?i of 14.2 (±0.7). The literature value 
of the caprylic acid pKa after correction for ionic strength was 4.71. The experimental 
pKa values and the corrected literature pKa values for caprylic acid were the same within 
experimental error, validating the silicone polymer membrane partition method for the 
determination of the capric acid pKa at 30°C and 0.37 ionic strength. 
3.5.1.2 HA* HPB and A~» HPB binding constants. Ku and K" 
Ku was determined from the results of the silicone polymer membrane 
partitioning experiments in the presence of 0.3, 1.0, and 3.0 mM HPB at pH 3.0 as 
described in Section 3.4.2.2. The apparent partition coefficients (kp>app) for capric acid 
partitioning into silicone polymer membrane at varying concentrations of HPB are shown 
in Fig 3,1, and the Fu and Ku for each condition are presented in Table 3.2. K~ was 
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Table 3.2 The capric acid/HPB binding constant (Ku) as 
determined from silicone polymer membrane 
partitioning coefficients at pH 3.0 in the presence of 
























determined as a best-fit K~ value with silicone polymer membrane alone capric acid 
transport data at pH 7.0 and 7.4 obtained in the presence of varying concentrations of 
HPB. The effect of the negative charge on the HPB binding constants have been reported 
by others for various ionizable lipophilic compounds.13'29 Finding Ku to be 
approximately three times larger than K~ is considered to be quite reasonable. 
3.5.1.3 Aqueous diffusion coefficients 
Sucrose has a well defined diffusion coefficient30 and has been frequently used as 
a standard;25'31 therefore, sucrose was used as the fritted glass disk cell reference solute 
for determining the aqueous diffusion coefficients using Eq 3.22. The aqueous diffusion 
coefficient of sucrose at 30°C taken from Ribeiro et al.32 was found to be 5.8 x 1CT6 cm2/s 
after correction for viscosity using: 
D E = — ^ D L (3-23) 
where T| is the viscosity, T is the absolute temperature, and D is the diffusion coefficient 
for the experimental and literature values (subscripts E and L, respectively). 
Table 3.3 presents the experimentally determined diffusion coefficients or 
effective diffusion coefficients and Table 3.4 presents the diffusion coefficients for the 
caprate«HPB complexes. The experimentally determined diffusion coefficients of urea 
and mannitol were found to be in good agreement with literature values ' " after 
correction for temperature and viscosity. D*~, the diffusion coefficient of the A~»HPB 
complex, was found by best-fitting all of the A~«HPB in Table 3.3 to Eq 3.4. D*u, the 
diffusion coefficient of the HA«HPB complex, was then calculated from the pH 3.0, 30 
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Table 3.3 Diffusion coefficients or effective diffusion coefficients (all at 30°C) for 
capric acid (HA), caprate ion (A~), mannitol, sucrose, and urea as a function of the 
hydroxypropyl-P-cyclodextrin (HPB) concentration (n>3). 
HPB cone. Diffusion coefficient or effective 


























































 Taken from reference and corrected for viscosity. 
b
 Diffusion coefficient 
c
 Effective diffusion coefficient 
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Table 3.4 Diffusion coefficients of the complexes calculated from the effective 
coefficients. 
Diffusion coefficient of the 


























mM HPB data (Table 3.3) and Eq 3.4. D" and Du differed by only a few percent. 
Likewise, D*~ and D*u also differed by only a few percent. Therefore, in order to 
simplify the calculations involved in the theoretical analysis of the experimental capric 
acid transport data, a single diffusion coefficient was selected for each pair by averaging 
the two values such that D~ = Du = Df and D*~ = D*u = D* where Df is the diffusion 
coefficient for both the free capric acid species and the caprate ion species, and D* is the 
diffusion coefficient for both of the complex species. Hence only Df and D* are given in 
Table 3.1. Therefore, for the present system Eq 3.4 reduces to 
Deff =D fF f +D*F* (3.24) 
where Ff and F* are the sum of the fractions of the two free caprate species and that of the 
two complexes, respectively. 
Because the viscosity of the buffer solution increased with increasing HPB 
concentration (up to -15% at 30 mM HPB, see Fig 3.2), the dependency of the individual 
diffusion coefficients upon the HPB concentration was considered. D for mannitol 
decreased by around 10% in the presence of 30 mM HPB, which is consistent with the 
viscosity increase at 30 mM but which is also within the data scatter. Within the data 
scatter (mostly 5 to 15%), the diffusivity of A~*HPB, was found to be relatively constant 
with respect to the HPB concentration (Table 3.4) and the diffusivity of HA»HPB, at 30 
mM was essentially the same as that of A~»HPB. The constancy of the diffusivity of the 
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Fig 3.2 Relative buffer viscosity as a function of the hydroxypropyl-P-
cyclodextrin (HPB) concentration of pH 3.0 and 7.4 buffer solutions. 
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for the stoichiometry of the complex. In any case, we are able to consider D* to be 
independent of HPB concentration in the model calculations. 
3.5.1.4 The determination of Pi and rum .SM from experiments 
with the silicone polymer membrane alone (SM) case 
Pi and 1IABL,SM were determined simultaneously from a procedure involving best-
fitting Eq 3.25 to a set of selected capric acid transport data (i.e., the PT values) obtained 
with the silicone polymer membrane alone (SM) case over a range of pH and in the 




 ABL.SM *->_ ,~ ~c\ 
1 ^ABL.SM , J J _ _ 
p p " nABL,SM p p u 
where PABL,SM is the aqueous boundary layer permeability coefficient for the capric acid 
molecule or that for the free caprate ion. Eq 3.25 comes from Eq 3.13: it follows from 
Eqs 3.4 and 3.5, when HPB is absent in the system, P^ L = P ^ S M and 
Df 
PABL.SM = ' where Df =6.9x10"6 cm2/s (see Table 3.1), and Fu is only a function of 
nABL,SM 
the pKa (4.53) and pH (see Section 3.8, Appendix B). The best-fit curve is in good 
agreement with the experimental results over the entire pH range with less than 5% 
deviation and yielded a 1IABL,SM value of 0.012 cm and a Pi value of 0.018 cm/s . 
Experimental variability was greatest in the low pH region (pH > pKa) where transport of 
the lipophilic capric acid was expected to be most sensitive to variations in the 
hydrodynamics of the diffusion cell system. The capric acid transport kinetics was 95-
Fig 3.3 Total permeability coefficient (PT) for capric acid transport across the 
silicone polymer membrane as a function of pH. Eq 3.25 with an input pKa value 
c ft 0 
of 4.53 and a D value of 6.9x10" cm /s was best-fitted to the experimental data 
(•) . The best-fit procedure simultaneously yielded a best 1IABL,SM value of 0.012 
cm and a best P; value of 0.018 cm/s). 
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97% ABL-controlled over the pH range of 3.0 to 5.5 and then markedly became 
increasingly membrane controlled with increasing pH. At pH 7.5, it was 97% membrane-
controlled. The good fit of the data, particularly in the high pH region, is also direct 
evidence that caprate ion transport across the silicone polymer membrane was negligible, 
and that therefore Pj accurately represented the transport of the neutral capric acid 
molecule across the silicone polymer membrane in the present system. 
3.5.1.5 Six Millipore membrane (MM) transport 
Table 3.5 shows Pj values for the transport of capric acid and mannitol across an 
assembly of six Millipore membranes in the presence and absence of 30 mM HPB at pH 
3.0 and 7.4. These transport experiments were performed to provide an independent 
estimate of the effective ABL thickness that the six Millipore membranes would provide 
as a surrogate ABL in the SM-MM experiments. The PT ratio for free capric acid to the 
HA«HPB complex was determined at pH 3.0 and 7.4 and compared to the same ratio as 
determined in the fritted disk diffusion coefficient studies. These ratios were consistent, 
which confirmed the absence of any significant diffusional pore hindrances (i.e., a 
hindrance factor of unity) for the transport of capric acid or the complex across the 
Millipore filters. Transport for all molecules was independent of pH within the scatter of 
the data which ruled out any pH specific effects. Because mannitol and capric acid had a 
similar molecular weight (180 and 172 Da, respectively), the total permeability 
coefficients (PT) for these molecules were compared at high and low pH. The similarity 
of the PT values of the two molecules ruled out lipophilicity dependent anomalies. The 
transport of mannitol in the presence and absence of 30 mM HPB was compared to rule 
Table 3.5 Total permeability coefficient (Pj) for transport of mannitol 
and of caprate species across six Millipore membranes in the presence 
and absence of 30 mM hydroxypropyl-|3-cyclodextrin (HPB) at pH 3.0 






































out any viscosity or HPB concentration-dependent anomalies, and the results were found 
to be consistent with the results of the fritted disk diffusivity experiments. Therefore, the 
six Millipore system was determined to be an acceptable surrogate ABL for the study of 
capric acid transport across the silicone polymer membrane in the presence of HPB. 
As an aside, a theoretical, surrogate ABL thickness of a six Millipore membrane 
assembly (hMM,theo) was calculated from 
h M M , t h e o = - ( 3 - 2 6 ) 
e 
where the actual thickness of six Millipore membranes (h) of 0.075 cm was determined 
using a micrometer and a porosity (e) of 0.7 and a pore diameter of 0.22 jxm were 
obtained from the manufacturer. Based on Eq 3.26 the liMM,theo was found to be 0.11 cm. 
The experimentally determined surrogate ABL thickness for the six Millipore membrane 
assembly, IIMM, was obtained from.the results of the mannitol transport experiments 
(Table 3.5) using 
h MM = DMannitol ( ~ ^ ) ( 3 ' 2 7 ) 
"T,MM - " A B L . S M 
Here PT,MM is the experimentally determined mannitol permeability coefficient for 
D .,, 
the six Millipore membrane assembly (Table 3.5) and PABLSM = —m a n m° w h e r e Dmannj t oi 
n ABL,SM 
is the mannitol aqueous diffusion coefficient (Table 3.3) and 1IABL,SM =0.012 cm is the 
ABL thickness for the system, previously defined (Table 3.1). The calculation with Eq 
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3.27 gives 1IMM=0.27 (± 0.04) cm. Independent of the calculation based on Eq 3.27, a 
value for 1IMM= of 0.23 (± 0.03) cm was obtained from the model best-fitting of capric 
acid transport data obtained in the silicone membrane plus six Millipore membrane (SM-
MM) system discussed in Section 3.5.2. Differences between the theoretical, surrogate 
ABL thickness of hMM,theo = 0.11 cm based on Eq 3.26 and the experimentally deduced 
hMM values are likely caused by several factors including Millipore membrane effective 
tortuosity values greater than unity and/or effective porosity values less than 0.7. The 
relatively small difference between the hMM values determined by the six Millipore alone 
experiments and Eq 3.27 and those based on the best-fit values to the silicone plus six 
Millipore membrane transport of the SM-MM experiments are within experimental error. 
In the model calculations, the value of hMM=0.23 cm has been employed. 
3.5.2 Capric acid transport experiments with the silicone membrane 
plus six Millipore membranes (SM-MM) system 
Fig 3.4 shows a family of log-log plots of capric acid PT versus HPB 
concentration ranging from 0-30 mM as a function of pH from 5.0-7.4 wherein the initial 
capric acid concentration, Cj, is comprised of 0.05 mM (cold) and 0.004 mM 
(radiolabeled). Generally, Pj decreases nonlinearly with increasing HPB concentration 
within each pH situation. It is observed that, using the parameter values in Table 3.1 and 
Eq 3.13, the model-predicted Pj values agree remarkably well with the experimental 
results over the entire range of the experimental conditions, as indicated by the solid 
curves. This underscores the validity of the physical model and the systematic approach 
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Fig 3.4 Total permeability coefficient (PT) for capric acid transport across the 
silicone membrane plus six Millipore filter (SM-MM) situation as a function of 
pH and hydroxypropyl-P-cyclodextrin (HPB) concentration. The solid curves 
represent the model-predicted values. The numbers represent the percent aqueous 
boundary layer (ABL) controlled transport. 
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parameters. The transport behavior of capric acid is attributed the multivariable 
interrelationships of the transport parameters (i.e., diffusion coefficients, intrinsic 
membrane permeability coefficient, effective aqueous boundary layer thickness) and the 
thermodynamic parameters (i.e., pH, pKa, partition coefficient, complexation equilibria, 
and species concentration) within the context of the transport barrier of the donor-side 
ABL and the silicone polymer membrane in series. Here, the governing diffusional 
resistance of the donor side effective ABL is due to the highly porous six Millipore 
membrane assembly for which the surrogate IUBL is 0.23 cm. Any contribution to the 
donor side diffusional resistance from the stirring-dependent, actual ABL of -0.012 cm is 
negligible. The receiver side ABL is effectively "short-circuited" by the pH 9.5 buffer 
condition. 
Focusing first on the pH 5.0 results (Fig 3.4), PT is 3.0xl0"5 cm/s in the absence of 
HPB in which case the passage of capric acid across the composite membrane system is 
essentially 100% effective ABL-controlled, i.e., by the six Millipore membrane assembly 
portion of the composite membrane. In the presence of HPB at 0.33 mM and 1.0 mM, 
the PT value has decreased to 2.1xl0"5 cm/s and 1.7xl0"5 cm/s, respectively. It can be 
noted, however, that in both instances the transport kinetics was still -100% effective 
ABL controlled. When the HPB concentration was increased to 30 mM, Pj decreased 
further to 9.5xl0"6 cm/s and now the transport kinetics was 67% ABL-controlled and 
33% silicone membrane-controlled. This behavior is the result of the following 
interrelationships. From a thermodynamic point of view, as the [HPB]/Cj ratio in the 
donor chamber increases, the free caprate fractions (capric acid molecule and the caprate 
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ion) decreases nonlinearly while the complementary fractions of caprate-HPB complexes 
increases nonlinearly. Since the effective aqueous diffusion coefficient is a sum of 
species-weighted diffusion coefficients (Eq 3.4), the permeability coefficient of the 
effective ABL (PABL=PABL,SM-MM) decreases nonlinearly with increasing HPB 
concentration, reaching a limiting value dictated by Eq 3.5 and the aqueous diffusivities 
of the HA«HPB complexes. At pH = 5.0, this limiting value for Deff is essentially 
attained at [HPB] -10 mM. In addition to this, since only the free, lipophilic unionized 
species (HA) may partition at the aqueous-silicone membrane interface, the effective 
silicone membrane permeability coefficient, Pm (see Eq 3.8), concomitantly also 
decreases nonlinearly with increasing (HPB) concentration. The consequence of both of 
these two factors is that the relative magnitudes of PABL,SM-MM and Pm will determine the 
extent to which the overall passive permeation processes described in PT is ABL- and/or 
silicone membrane-controlled (Eq 3.13). 
In the case of pH 7.4 and comparing it to the pH 5.0 case, the displacement of Py 
to smaller values at each HPB concentration is largely influenced by the interplay of 
pH/pKa, the predominance of free caprate ion (A~) and A~«HPB fractions, and the 
restriction that only free capric acid molecule (HA) may permeate the silicone membrane. 
Hence, it is observed that the overall transport kinetics is less ABL controlled in the 
absence of HPB and becomes more membrane-controlled with increasing HPB 
concentration. 
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3.5.3 Transport experiments with silicone membrane alone (SM) 
The transport experiments of capric acid with SM in the presence of HPB was to 
show the effects of HPB on capric acid transport when the ABL is thin (0.012 cm) 
compared to the previously discussed (SM-MM) thick (0.23 cm) ABL case. This SM 
case may be regarded as typical of single silicone membrane transport situation with 
conventional hydrodynamic conditions (stirred aqueous compartments). The experiments 
were conducted under the same solution conditions as in the SM-MM case, and the 
results are presented in Fig 3.5. As with the SM-MM case, the model predicted Pj for 
capric acid transport across SM agree quite well over the entire ranges of pH and HPB 
concentrations and covers, for the most part, the 100 percent ABL-controlled to the 100 
percent membrane-controlled range. The capric acid transport behavior in the SM case 
(Fig 3.5) is seen to differ from the SM-MM case (Fig 3.4) as follows. Because of the 
much thinner ABL (0.012 cm vs. 0.23 cm) in the case of SM, capric acid transport is 
more membrane-controlled (rather than ABL-controlled) over a wider range of conditions 
relative to the SM-MM case (Fig 3.4). Thus, convergence to ABL-controlled transport in 
the absence of HPB occurs at lower pH, i.e., around pH 4 to 5 in the SM case, instead of 
around pH of 6 to 7 as seen in the case of the SM-MM. For the same reason, the 
dependence of capric acid transport upon the HPB concentration at constant pH is steep 
over the entire HPB concentration range for the high pH situations (~ pH 7.0) in Fig 3.5 
(SM case) but not as much in Fig 3.4 (SM-MM case). This is because, in the latter case, 
the capric acid transport is already substantially ABL-controlled at zero or low HPB 
concentrations even at pH 7.0 and becomes predominantly membrane-controlled only at 
the high HPB concentrations. It should be noted that, in the comparison of the physical 
10" 
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Fig 3.5 Total permeability coefficient (PT) for capric acid transport across the 
silicone membrane alone (SM) as a function of pH and hydroxypropyl-p% 
cyclodextrin (HPB) concentration. The solid lines represent the model-predicted 
values. The numbers are the percent aqueous boundary layer (ABL) controlled. 
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model predictions with the experimental data, the SM case is more sensitive than the SM-
MM case to more of the parameters in Table 3.1 over the range of conditions 
investigated. This is because of the greater influence of the ABL in the case of SM-MM. 
This does raise the question of how well the physical model would have been tested if we 
had experimental data only from the SM-MM case. The membrane-controlled conditions 
are particularly sensitive to the pKa, Pi, and K~, while the ABL-controlled conditions are 
primarily sensitive to the diffusion coefficients and both KT and Ku. The good agreement 
between physical model predictions and the experimental data employing both the SM 
and the SM-MM cases is therefore strong evidence for the validity of the physical model 
and that of the input parameters (Table 3.1) used in the calculations. 
3.5.4 Radiochemical impurity corrections for capric acid 
transport and for the transport parameter values 
At the beginning of the present research, the stock [14C]capric acid was checked 
for radiochemical purity by HPLC fraction collection with 98-100% of the DPM 
recovered in the capric acid peak (retention time of 11 min). This was in agreement with 
manufacturer's claims (>97%). Initial silicone membrane alone (SM) [14C]capric acid 
transport experiments however suggested, in some cases, a higher percentage of 
radiochemical impurity(ies) in the receiver chamber than expected, especially at high pH 
and high HPB concentration. Therefore a special set of high concentration (14 u£i/ml) 
[14C]capric acid transport experiments were conducted with the aim to more 
quantitatively assess the impurity problem. The results of these experiments allowed for 
the determination of the initial concentration of the impurity and the impurity 
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permeability coefficient. This information allowed us to make corrections for the effect 
of the impurity upon the capric acid fluxes, and these corrections have been incorporated 
in the results presented in Figs 3.3, 3.4, and 3.5. Corrections were also estimated for 
those transport parameters affected by the impurity and in all cases these were within 
experimental error. The details of the impurity study are presented in Appendix A. 
3.6 Discussion 
In light of the results demonstrated by Fig 3.4 and Fig 3.5, we may now discuss a 
scenario of how the presence of a cyclodextrin such as HPB in a formulation may 
improve the bioavailability of a drug. 
3.6.1 Flux of drug X across SM-MM at unit thermodynamic 
activity (saturated solutions) 
Let us discuss the potential implications of the results of the SM-MM studies of 
capric acid transport as it may apply to a typical aqueous-based drug formulation problem 
involving a hypothetical weak acid drug, X, having the same parameter values as those of 
the capric acid-silicone polymer membrane system (Table 3.1). The saturated solution of 
crystals of X in any formulation will possess a thermodynamic activity, a=l. Therefore, 
excluding supersaturated solutions from consideration, any pharmaceutical solution 
formulation of drug X at a=1.0 would be that possessing the potential for providing the 
maximum flux, Jmax, across the membrane system. We may now define Rj,max as the ratio 
of Jmax (=Jmax,f) of a test HPB formulation of drug X to Jmax (=Jmax,o) of the saturated 
solution of X in essentially pure water at low pH (i.e., pH « 4.53). Rj,max should then be 
a measure of the transport flux enhancement for any HPB formulation of drug X at 
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saturation relative to the saturated solution of X in water at low pH where only the 
unionized species of X is present in solution. From Eqs 3.1, 3.4, 3.5, and 3.12 and using 
the same terminology and symbols for the drug X/HPB system as for the capric acid/HPB 
system, we may write 
J =CU 
max,o sat.soln " A B L 




™«.f sat so In 
f 1 N 
v F u , 'ABL 
eff D 
+ • 






" A B L 
Du i J 
1ABL 
eff D RFU 
(3.30) 
Here Cu is the concentration of the saturated solution of X in pure water at low pH 
sat so In A J. 
(pH «pK a ) , hABL=hABL,SM-MM (Table 3.1), and all other terms have been previously 
defined. 
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Fig 3.6 presents plots of Rj,max versus HPB concentration at different pH of the 
hypothetical formulations. Several outcomes of interest relative to formulation 
performance now become clear that were not easily discernable from Fig 3.4, and the 
interplay of pH, HPB concentration, IIABL. and Pj becomes more apparent. With respect 
to the addition of HPB, it can be seen in Fig 3.6 that the greatest influence of HPB upon 
the X flux enhancement takes place at the lowest pH (i.e., p H « 4.53) with the 30 mM 
case increasing the flux by around 30-fold over the formulation of X alone. The least 
increased X flux enhancement from the addition of HPB occurs with the pH 7.4 case, 
with the 30 mM case increasing the X flux by less than 2-fold over the X alone 
formulation at pH 7.4. It can also be seen from Fig 3.6 that, at a=l, the X flux increases 
with increasing pH for a given HPB concentration. This demonstrates that the X anion 
may have an effect similar to that of the X«HPB and the X~»HPB complexes, i.e., to act 
as a carrier for X across the ABL (but it must be remembered that the formulation is 
assumed to possess high buffer capacity in the present calculations). From the 
mechanistic standpoint, in the steady-state transport of the unionized and the ionized X 
species across the ABL with adequate buffer capacity in the aqueous phase to preclude 
any significant pH gradients in the ABL, the ratio of the ionized to unionized drug 
species increases with increasing pH and therefore the ratio of the fluxes of the two 
species increases; and, because at a=l the unionized concentration of X is constant in the 
donor chamber solution, the total flux of X may also increase as long as the overall 
transport of X is sufficiently ABL controlled. It is interesting to note that, while in going 
from 0 HPB to 30 mM HPB, the percent increase in Rj,raax is greatest for the lowest pH 
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Fig 3.6 The influences of the HPB concentration and pH upon the flux 
enhancement factor, Rj,max, for saturated solutions of drug X across the silicone 
membrane plus six Millipore membrane filters (SM-MM). 
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considerably greater than for 30 mM HPB at the lowest pH. This points out that pH can 
be more important than the HPB concentration in enhancing the flux for the drug X 
system with the Table 3.1 parameters. 
Even though only the free, unionized X molecule can traverse the silicone 
membrane, all four of the X species can traverse the ABL. Therefore, the complexes and 
the X anion species can help increase the X flux across the system, but only to the extent 
that it can effectively reduce the transport resistance of the ABL. There would be no 
further benefit of increasing the carrier concentration when X transport becomes 
essentially membrane-controlled. This can be seen by the plateau in Fig 3.6 at the two 
highest pHs. A carrier cannot increase the X flux beyond this point because this value 
represents membrane-controlled transport limit. 
3.6.2 Flux of drug X across the rat ileum 
at unit thermodynamic activity 
It should now be instructive to apply the above results in examining flux 
enhancement of drug X in the scenario of in situ drug absorption studies of the rat ileum. 
For the physical model calculations of drug X transport in the rat ileum, all of the 
parameters of Table 3.1 would apply except for the intrinsic permeability coefficient (Pi) 
and the aqueous boundary layer thickness (IIABL)- For the rat ileum calculations, we may 
employ Pi =3.5 cm/s and hABL = hABWieum = 0.117 cm; both of these parameter values are 
taken from the results of a study of the influence of HPB on capric acid absorption in the 
rat ileum (Table 4.6 in Chapter 4). 
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Fig 3.7 presents plots of Rj,max vs. HPB concentration at various pH conditions for 
the rat ileum case. In comparing Fig 3.7 to Fig 3.6, we note a number of points of 
interest. At low pH (pH«4.53) at which only the free unionized drug X and the X»HPB 
complex species should exist, the plots in the two figures converge to a common limiting 
curve. This is because transport across the silicone membrane and the rat ileum is 
essentially 100% ABL-controlled throughout the HPB concentration range and 
consequently, the ABL thickness in each case cancels out in the calculation of Rj,max- At 
high pH, there are significant differences between the Fig 3.7 and Fig 3.6. In Fig 3.6, as 
noted already, the curves at high pH exhibit little dependence upon HPB concentration 
and essentially converge to a constant plateau as a function of pH at around pH 7.4. In 
contrast to this behavior, the curves at pH 7.4 in Fig 3.7 continue an upward displacement 
with increasing pH and continue to exhibit a moderate-to-strong HPB concentration 
dependence everywhere. On the latter point, at pH 7.4 in going from zero HPB to 30 mM 
HPB, the Rj,max value increases by a factor of around 30 in the case of the rat ileum while, 
as noted earlier in the case of SM-MM, this increase was less than a factor of two. These 
differences between Fig 3.6 and Fig 3.7 are largely the result of the much larger P; for 
the rat ileum (i.e., 3.5 cm/s for the rat ileum vs. 0.018 cra/s for the silicone polymer 
membrane) and of the quantitative interplay between the respective effective permeability 
coefficient, P ^ L , and Fu. The above comparison between the SM-MM results (Fig 3.6) 
and the rat ileum results (Fig 3.7) points to the potential value of the physical model 
approach in formulation development of highly lipophilic, low solubility drug molecules 
in oral delivery. To have had only the experimental silicone membrane transport data for 
drug X and some intuitive judgment to assess the potential of HPB as a drug carrier could 
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Fig 3.7 The influences of the HPB concentration and pH upon the flux 
enhancement factor, Rj,max, for saturated solutions of drug X transport across the 
rat ileum. 
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have led to the erroneous conclusion that there would be little or no favorable effect of 
HPB, in vivo, to enhance absorption of drug X. The physical model approach may thus 
provide the framework for the measurements of key parameters and their quantitative 
relationships which could then be applied judiciously to predicting in vivo situations. 
3.7 Appendix A. Radiochemical Impurity Corrections 
for Capric Acid Transport Parameter Values 
An initial set of transport experiments was carried out with a high concentration 
(14 (iCi/ml) of [14C]capric acid in the donor chamber, and the amount of the impurity 
transported into the receiver chamber at 100 minutes determined. The conditions of the 
experiments otherwise were as described in Section 3.4.2.5. The results are presented in 
Fig 3.8. Importantly, the impurity fluxes (data not shown), when normalized for the total 
DPM in the donor chamber solution, were found to be essentially the same in all of the 
experiments. This immediately indicated that the thermodynamic activity of the 
transported impurity species in the donor chamber was independent of both the pH and 
the HPB concentration. Based upon this information, the following experiment was 
conducted. 
A silicone membrane alone transport experiment with an initial donor solution of 
14 (iCi/ml [14C]caprate plus 30 mM HPB at pH 7.4 was run for 1500 minutes with 
complete replacement of the receiver chamber solution at 100 minute intervals, and each 
of these receiver chamber solutions was analyzed for the total amount of the impurity. 
The initial impurity concentration (DPM/ml) in the donor chamber, Cimp,init, was 
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Fig 3.8 Experimental and predicted percent radiochemical impurity in the receiver 
chamber after 100 minutes The percent radiochemical impurity in the receiver 
chamber at 100 minutes during [14C]capric acid transport across the silicone 
membrane alone under various pH and HPB concentration conditions (symbols). 
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Here XAimp>tot is the total cumulative amount of the impurity transported into the receiver 
chamber over the 1500 minute run; Ajmp?ioo is the amount of impurity (DPM) found in the 
0-100 minute receiver solution; Aimp>i5oo is the amount of impurity (DPM) found in the 
1400-1500 minute receiver solution; VD = 2.0 ml is the volume of the donor solution. 
Then, the percent radiochemical impurity in the stock [14C]capric acid solution may be 
calculated from 
% impurity = CimpMt (3.32) 
^DPM.tot 
where CDPM, tot is the total initial radioactivity concentration (DPM/ml) in the donor 
chamber. Eq 3.31 has assumed that the impurity transport is a first order process. Using 
Eqs 3.31 and 3.32, the stock [14C]capric acid solution was determined to have a 0.64% 
impurity which was in agreement with the manufacturer's claims. However, when the 
fraction of the free capric acid species available for transport is very small (i.e., F u « l ) , 
this small amount of impurity in the stock [14C] capric acid solution is responsible for a 
significantly high percentage of the radiochemical flux. Fig 3.8 shows the experimental 
and predicted percent impurity in the receiver chamber after 100 minutes for several 
capric acid transport conditions. The predicted values were based on the experimental 
permeability coefficient of the radiochemical impurity, Pimp, 
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imp 
where Jjmp is the experimental impurity flux and Cimp is the impurity concentration in the 
donor chamber. As noted earlier, Jirap/Qmp was found to be constant in all 
experiments, corresponding to Pjmp=4.6xl0" cm/s. The constancy of the Pimp value 
importantly verified that the thermodynamic activity of the impurity was insensitive to 
pH and the HPB concentration over the range of conditions studied. This outcome 
allowed for the direct prediction of the theoretical values in Fig 3.7 using Eq 3.33. The 
Pimp value has also permitted impurity corrections to be applied to the experimental data 
presented in Figs 3.4 and 3.5. These figures can be compared with Figs. 3.9 and 3.10, in 
which the experimental data and the model-predicted curves are based on the uncorrected 
PT data. The corrections were important only at high pH and high HPB concentrations. 
Where they were important, they generally improved the fit of the experimental data to 
the model predictions. 
In addition to the impurity correction of Pj values for capric acid transport across 
the silicone polymer membrane, the impact of the impurity upon the determination of the 
capric acid pKa and the caprate/HPB binding constants Ku and K~ was also assessed. The 
capric acid pKa was experimentally determined from capric acid partitioning between the 
silicone polymer membrane and the aqueous phase. The maximum possible errors 
arising from the impurity(ies) in the partition coefficient experiments can be assessed by 
examining the two extreme cases: none or all of the impurity partitions into the silicone 
polymer. In the case where none of the impurity partitions into the silicone phase, the 
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Fig 3.9 The results presented here (both the experimental and the model-
predicted values) are the same as those of Fig 3.4 except the corrections for the 
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Fig 3.10 The results presented here (both the experimental and the model-
predicted values) are the same as those of Fig 3.5 except the corrections for the 
impurity fluxes were not made. 
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concentration (Caq) will have maximum error (see Eq 3.14). Recall that the initial 
concentration of impurity was 0.64%; however, as capric acid partitions into silicone, the 
impurity is left behind, and the fraction of the impurity in the aqueous phase is increased. 
This situation will be most extreme for the low pH case (i.e., pH 3.5) where the 
partitioning of capric acid into the silicone phase is greatest (i.e., the highest kp?app, see 
Fig 3.1). For this case, the aqueous concentration of the total radioactivity (DPM/ml) at 
equilibrium would have been reduced to 57% of its initial concentration while the 
concentration of the impurity in the aqueous phase would have remained unchanged. 
This would have increased the radioactive impurity fraction from 0.64% to 1.12% of the 
total radiolabeled material in the aqueous phase, which would still be negligible. For the 
other extreme case where all of the impurity partitions into the silicone membrane, the 
capric acid concentration in the aqueous phase (Caq) will remain as correct and the capric 
acid concentration in silicone (Cs,p; see Eq 3.14) would have maximum error. The 
maximum error would occur at the highest pH (i.e., pH 5.5 was the highest pH for which 
data were used in the best-fit procedure to determine the pKa value of capric acid.) 
because it would correspond to having the smallest fraction of capric acid partitioning 
into silicone (i.e., it has the lowest kp,app). In the pH 5.5 experiment, the total DPM in the 
system were 450,000 DPM, of which 35,000 were in the silicone membrane at 
equilibrium. The total amount of impurity in the system was 2,880 DPM 
(450,000x0.0064). If all of the impurity DPM partitioned into the silicone membrane, the 
experimental Caq at pH 5.5 would have had an 8.2% error, with the lower pH data 
exhibiting smaller errors. In order to assess the maximum possible effect the impurity 
could have on the pKa determination, the pKa was reevaluated after subtracting all the 
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assumed impurity DPM from the silicone phase. The result was a pKa of 4.51 (±0.03) and 
a kP)j of 311(±14), both which are within the experimental error of the original evaluation. 
Because the true partition coefficient of the impurity was not known and the maximum 
effect was negligible, the original pKa and kp>i values were retained for use in all 
calculations. 
The determination of Ku required silicone partitioning studies at pH 3.0 with 0, 
0.33, 1, and 3 mM HPB, where the kp,app values were 303, 97, 38, and 14, respectively 
(see Fig 3.1). If we again assume that all the impurity partitions into the silicone phase, 
then as before the most extreme error due to impurity would occur when kp,app is lowest 
(i.e., the 3 mM HPB case). In this case there were 430,000 DPM in the system, of which 
17,000 DPM would have been in the silicone at equilibrium. If all the impurity (2750 
DPM) is assumed to have partitioned into the silicone phase, then the actual kPjapp would 
have been 17% lower than the experimentally determined kP;app, with the lower HPB 
conditions experiencing lower maximum errors. Reevaluating Ku under this extreme case 
where the impurity had an infinitely high silicone partition coefficient by subtracting all 
the impurity DPM from the silicone phase for all cases yielded a Ku value of 7.7 (±0.3), 
which is within experimental error of the reported value (7.5 (±0.3, see Table 3.1). 
Therefore, no corrections were made to Ku. K~ needed no evaluation since it was 
determined by best-fitting to impurity-corrected silicone transport data. In conclusion, 
only the PT values needed correcting for the small amount of impurity present in the stock 
[14C]capric acid solution. Table 3.6 compares the uncorrected to the corrected for the 
worst cases for pKa, kp?i, and Ku. 
Table 3.6 A comparison of parameters and PT results before and after 
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3.8 Appendix B. Equilibrium Reactions. Species 
Concentrations and Fractions 
The equilibrium reaction of capric acid (HA) and its acid dissociation constant Ka, 
are 
HA< >H++A" 
t i ne : 
cu 
For the complexes of HPB with the caprate species, HA» HPB and A • HPB, the 
equilibria are: 
HPB + HA ( K" ) HA • HPB 
HPB + A" ( K >A~ • HPB 
The binding constants Ku and K , are: 
Ku = - (3.35) 
Cu[HPBf] 
K " = (3.36) 
CT[HPBf] 
where C*u, C* , and [HPBf] are the concentrations of the HA* HPB, A • HPB, and free 
HPB, respectively. The total caprate concentration, CT, is 
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CT =CU+CT+C*U+C*" (3.37) 
And, in terms of the fraction (F) of each species, 
CT = (Fu + F - + F*u + F " )CT (3.38) 
The total concentration of all HPB species, [HPBT], is 
[HPBT ] = [HPBf ] + C*u + C*" (3.39) 
Solving for the concentration of each species in Eq 3.37 with the aid of Eqs 3.34, 3.35, 
3.36, and 3.39, one obtains expressions which take into account the pH and pKa, the 
binding constants Ku and K~, and the [HPBT] and CT. 
Capric acid species 
C u = ^ (3.40) 
p + a[HPBf] 
[HPBT] 
[HPBf] = i T— (3.41) 
f
 l + aCu 
aP(Cu )2 + [p + a[HPBT ] - aCT] Cu - CT = 0 (3.42) 
where 
a = Ku+K-(10 (pH-pKa)) (3.43) 
P = l + 10(pH"pKa) (3.44) 
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Caprate ion species 
C= ^1 (3.45) 
P'+o'[HPBf] 
[ H P B f ] = I ^ l (3.46) 
1 + a 'C -
a'p(C-)2 +\p+a'[HPBT]-a:CT] C - C T = 0 (3.47) 
a'=K-+Ku(10(pK°-pH)) (3.48) 
p '=l + 10(pKa"pH) (3.49) 
HPB »A~ Complex 
C*"= ^ (3.50) 
l | K"(P'-1) | P' 
K - K[HPB f ] 
Y[HPBf]2 + [l + yCT-Y[HPBT]] [HPBf ]-[HPBT] = 0 (3.51) 
where 
y = ^ + - (3.52) 
P' P 
80 
HPB »HA Complex 
C*u =C T - (C U +CT+C*- ) (3.53) 
The quadratic formula is applied to the solutions of the binomial equations. When the 
concentration ratio of [HPB
 T] /CT is much greater than unity, say 100, [HPB f] =[ HPBT], 
which would simplify the calculations of the specific species concentrations. The 
fraction of each species is calculated using 
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C~ 
D 
free caprate ion 
membrane surface area 
thermodynamic activity 
aqueous boundary layer 
caprate ion«HPB complex 
solution containing both caprate ion and HPB (pH 7.4) 
the sum of impurity DPM over the 1500 minute run 
the impurity DPM found in the 0-100 minute receiver sample 
the impurity DPM found in the 1400-1500 minute receiver sample 
concentration 
concentration of capric acid in the silicone polymer 
membrane 
concentration of total caprate in the aqueous phase 
total initial concentration of radioactivity in the donor 
chamber 
initial concentration of impurity in the donor solution 
total caprate concentration 
concentration of solute in a donor solution 
concentration of total caprate in donor solution 
concentration of total caprate at the membrane surface 
concentration of free capric acid 
concentration of the saturated solution of X in pure water at 
low pH 
concentration of free caprate ion 
concentration of capric acid»HPB complex 
concentration of caprate ion»HPB complex 
diffusion coefficient 
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Dm diffusion coefficient of capric acid in the silicone polymer 
membrane 
Dx diffusion coefficient of the permeant of interest 
DR diffusion coefficient of the reference permeant 
Du diffusion coefficient of the free capric acid species 
D~ diffusion coefficient of the free caprate ion species 
D*u diffusion coefficient of the capric acid«HPB complex 
D*~ diffusion coefficient of the caprate ion»HPB complex 
Df diffusion coefficient of free capric acid or of caprate ion 
D* diffusion coefficient of capric acid«HPB complex or of the 
caprate ion»HPB complex 
Deff effective diffusion coefficient 
D E experimental diffusion coefficient 
DL literature value of the diffusion coefficient 
DPM disintegrations per minute 
F fraction 
Fu fraction of the free capric acid species 
F~ fraction of the free caprate ion species 
F*u fraction of the capric acid«HPB complex 
F*~ fraction of the caprate ion«HPB complex 
Ff sum of the fractions of the capric acid and the caprate ion 
species 
F* sum of the fractions of the HA»HPB and the A~«HPB 
complexes 
h thickness 
hm thickness of the silicone polymer membrane 
hABL aqueous boundary layer thickness 


























effective aqueous boundary layer thickness for the silicone 
membrane plus six Millipore membranes 
experimentally determined surrogate ABL thickness for the six 
millipore membrane assembly 
theoretically predicted surrogate ABL thickness of a six Millipore 
membrane assembly 




the total concentration of all HPB species 
capric acid*HPB complex 
solution containing both capric acid and HPB (pH 3.0) 
flux 
flux across the membrane 
maximum flux across the membrane system 
maximum flux of a test formulation containing drug X and 
HPB 
maximum flux of a test formulation in pure water at low pH 
flux across the ABL 
impurity flux 
capric acid»HPB binding constant 
caprate ion»HPB binding constant 
dissociation constant 
intrinsic partition coefficient 
apparent partition coefficient 
total permeability coefficient 
permeability coefficient across six Millipore membranes 




























intrinsic membrane permeability coefficient 
effective membrane permeability coefficient 
the ABL permeability coefficient in the absence of a carrier 
the ABL permeability coefficient in the absence of a carrier in the 
SM experiments 
the ABL permeability coefficient in the absence of a carrier in the 
SM-MM experiments 
permeability coefficient of the permeant of interest 
permeability coefficient of the reference permeant 
impurity membrane permeability coefficient 
ABL permeability coefficient in the presence of a carrier 
ratio of Jmax,f to Jmax,0 
silicone membrane alone transport model 
six Millipore membranes alone transport model 
silicone membrane plus six Millipore membranes transport 
model 
absolute temperature 
experimental absolute temperature 
literature absolute temperature 
volume in the donor chamber 
hypothetical drug molecule with the same transport parameters as 
capric acid and a solubility of 0.05 mM 
compound X»HPB complex 
compound X anion*HPB complex 
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CHAPTER 4 
CAPRIC ACID ABSORPTION IN THE PRESENCE OF 
HYDROXYPROPYL-p-CYCLODEXTRIN IN THE 
RAT ILEUM USING THE IN SITU SINGLE 
PASS PERFUSION TECHNIQUE 
4.1 Introduction 
While there has been much progress from the practical standpoint in the area of 
oral drug formulation development involving cyclodextrins,1"5 there has been relatively 
little progress from the standpoint of obtaining a quantitative mechanistic understanding 
of the interplay of key variables involved in the intestinal absorption enhancement by 
cyclodextrins. In Chapter 3 we developed a physical model, which we called the flat 
surface model (FSM) that should represent an important step toward the mechanistic 
understanding of the transport of highly lipophilic, ionizable drug molecules between two 
aqueous compartments separated by a lipophilic membrane and where a carrier such as a 
cyclodextrin is present in the aqueous phase. Capric acid permeability coefficients 
predicted by the FSM equations describing the permeant transport behavior in the 
presence of a carrier were found to be in good agreement with the experimental results 
for capric acid transport between two aqueous compartments separated by a silicone 
polymer membrane over wide ranges of pH and the 2-hydroxypropyl-P-cyclodextrin 
(HPB) concentrations. The good agreement of experimental data with the FSM-
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predictions over the range of conditions demonstrates the rigor of the model and the 
appropriateness of extending the applications of the FSM approach to other transport 
situations and conditions. The FSM was able to quantitatively demonstrate the interplay 
of key variables such as solution pH, capric acid pKa, caprate species-HPB binding 
constants, aqueous boundary layer thickness, diffusion coefficients, and the capric acid 
lipophilicity and to demonstrate the relative importance of each of these variables for a 
given set of transport conditions. 
A main purpose of establishing the FSM approach in Chapter 3 was to establish a 
sound physical model that could be used to probe the effects of HPB on the transport of 
lipophilic molecules across biological membranes, more specifically the intestinal 
membrane. One concern about using cyclodextrins in oral formulations is that of safety. 
As with any potential excipient, questions arise concerning possible adverse side effects. 
While unsubstituted cyclodextrins and cyclodextrins with lipophilic substitutions have 
ft 7 
been shown to cause damage to erythrocytes and biological membranes, ' the relatively 
high degree of safety of HPB in oral formulations has been well documented.8"13 It has 
been demonstrated that HPB concentrations up to 100 mM do not appear to extract 
relevant lipids from biological membranes or otherwise disrupt the integrity of epithelial 
cells.14"16 In addition to HPB being well tolerated, it is highly water soluble and not 
significantly absorbed in the gastrointestinal tract.1'2 These characteristics make HPB a 
good candidate for a solubilizing agent in oral dosage form design. Accordingly, the 
FDA has included HPB in its list of Inactive Pharmaceutical Ingredients.1 In fact, HPB 
has already been used in approved and marketed drug formulations in Europe, Japan, and 
the United States, with several more formulations in clinical trials.17 
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The initial aim of the current study was to gain further insight into the role of 
cyclodextrin carriers in improving the oral bioavailability of highly lipophilic molecules 
by applying the FSM to results from intestinal absorption experiments involving the rat 
ileum. Capric acid and HPB are used to represent a typical, highly lipophilic weak acid 
molecule and a carrier molecule, respectively. The interplay of key variables, their 
relative importances under various experimental conditions, and the mechanism by which 
cyclodextrins may improve oral bioavailability were to be examined. An additional aim 
of this study was to adapt and extend the FSM to allow for a more detailed examination 
of the rat ileal intestinal absorption problem. Accordingly, a villus model (VM) that 
takes into account the villus architecture of the ileum is also presented. Each of the 
models are examined in light of the experimental data for capric acid absorption in the rat 
ileum at pH 7.4 in the presence of 0 - 50 mM HPB. 
4.2 Strategy 
4.2.1 The experimental method and the 
estimation of key FSM parameters 
The technique of in situ single pass perfusion of an isolated rat ileal segment and 
local mesenteric venous blood collection is used.18'19 As the perfusing permeant (i.e., 
capric acid) solution flows down the rat ileum, taken as a cylinder with a smooth inner 
surface, at a constant rate, the permeant is absorbed across the epithelial cells into a blood 
sink. The perfusion flow rate is strictly controlled using a perfusion pump, and the exit 
concentration of the permeant and the osmolarity of the perfusate are assayed at regular 
time points. Mesenteric venous cannulation provides the means for the determination of 
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the permeant appearance rate in the blood draining the intestinal segment. This allows 
for a more sensitive determination of steady-state flux as compared with methods which 
determine the permeant flux from the disappearance kinetics in the lumen. The gut 
length and the inside diameter are measured for the flat surface area determination (flat 
surface area refers to treating the intestinal gut segment as a hollow smooth circular 
cylinder), and the mean permeant concentration in the lumen is determined from initial 
and exit concentrations of the permeant. With the mean luminal concentration, 
membrane surface area, and appearance rate of permeant in the blood, the permeant flux 
(Jb) and the total permeability coefficient (Pj) are directly determined. Further details are 
explained in the methods and data treatment sections. 
Key parameters of the flat surface model (FSM) developed in Chapter 3 were 
intended for application in the intestinal perfusion studies. With the exception of the 
aqueous boundary layer thickness (IUBL) and intrinsic membrane permeability coefficient 
(Pi), the previously determined parameters (Table 3.1) are applicable to the intestinal 
perfusion of capric acid in the presence of HPB and are listed, along with the appropriate 
IIABL and Pi for the present study, in Table 4.1. The IIABL is dependent upon the 
hydrodynamics and therefore must be determined experimentally under the same 
experimental conditions as those of the perfusion experiments in this study. The IUBL 
was determined to be 0.117 cm by a best-fitting procedure (as described in detail in the 
results section) involving the experimental data over the range of HPB concentrations at 
pH 7.4. Taurocholate, which is actively absorbed in the rat ileum and which is 
completely aqueous boundary layer (ABL) controlled, was used to confirm the IIABL 




















































































































































































































































































































































































































































































was consistent with the IIABL determined previously in our laboratory (0.109 cm) for the 
same perfusate flow rate.18 The best-fit IIABL of 0.117 cm was chosen for the purposes of 
this study. The estimation of P, was initially thought to be problematic. Although capric 
acid alone transport across the silicone polymer membrane was shown in Chapter 3 (the 
silicone membrane alone case experiments) to be essentially membrane-controlled at pH 
7.4, preliminary intestinal perfusion experiments indicated that capric acid alone 
absorption was 100% ABL-controlled at pH 7.4 in the rat ileum and therefore Pj was 
thought to be insensitive to quantification. However, as will be seen, the HPB carrier 
investigation itself provided a means for obtaining a reasonably good estimate of Pi 
because, as was shown in Chapter 3, with increasing HPB concentration capric acid 
transport becomes increasingly membrane-controlled. Thus, the capric acid transport 
experiments in the presence of varying concentrations of HPB (0-50 mM) provided a 
means for determining both IIABL and Pi by best fitting of both parameters to the entire 
range of experimental data. 
In the present in situ perfusion experiments, the buffered condition of pH 7.4 was 
regarded to hold, not only in the bulk luminal solution, but also across the ABL and in the 
intervillus spaces, i.e., no significant pH gradients are expected to exist in the ileum for 
two reasons. Firstly, the buffer capacity ((3) of 0.057 M sodium phosphate at pH 7.4 is 
3.13 x 10"2 M.20 Caprate (5 x 10"5 M cold and 0.4 x 10"5 M radiolabeled), correspond to a 
total caprate concentration (Cj) of 5.4 x 10"5 M). Therefore any pH gradient (ApH) 
should be insignificant: 
ApH = - I 5 L ! = - . £ L = -0.0017 (4.1) 
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Secondly, the microclimate pH about the rat ileal membrane surface, owing to the 
continuous flow of alkalinized secretions from intervillus secretory cells, has been found 
to be pH 7.3 21'22. In contrast, the secretory cells in the jejunum maintain a more acidic 
microclimate pH 6.0 environment; in the latter case there may be the potential to sustain 
pH gradients if the luminal solution pH was buffered at pH 7.423, and for this latter more 
complex situation, a physical model has yet to be written. On a somewhat different but 
related issue, the open-ended intraluminal perfusion of pH 7.4 buffered solution of capric 
acid and HPB mixtures from an infinite reservoir at 0.2 ml/min (or linear flow velocity of 
1.6 cm/min) would also preclude the existence of any longitudinal pH gradient along the 
10 cm ileal segment as well as any significant accumulation of secretions in the perfusate 
with time. 
4.2.2 Flat surface versus villus surfaces 
In addition to different FSM IIABL and Pj parameter values when compared to the 
in vitro silicone polymer membrane transport system (Chapter 3), the in situ single pass 
perfusion system involves key fluid flow and geometry differences. The permeant 
solution flows into and out of the isolated ileal segment in the intestinal perfusion 
experiment, whereas the permeant solution is confined to a magnetically stirred donor 
compartment in the side-by-side diffusion cell experiment. Another key difference 
between the intestinal perfusion experiments and the silicone polymer membrane 
experiments is that the surface of the rat ileum is covered with villi which may 
significantly increase the effective surface area utilized for absorption compared to the 
smooth (flat) surface of the silicone polymer membrane. Accordingly, we also examine a 
modified physical model which should be more appropriate to the intestinal transport 
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experiments and is termed the villus model for intestinal absorption (VM). This villus 
model incorporates the height, diameter, and density of the villi as well as the mean 
intervillus space. Winne24'25 and Oliver et al.2 have previously idealized the structure of 
the villi using a two-dimensional model with an intervillus space of given height and 
width that represents the villi as rectangular columns with a mean villus diameter. Using 
a similar approach, we idealize the villus structure using a 2D axial symmetry model (see 
Fig 4.1, Table 4.2, Fig 4.2, and Table 4.3) that represents the villi as circular-cylindrical 
columns of a given height and diameter with a defined intervillus space represented by an 
annular cylinder, coaxial with the villus, having a cross-sectional area of the average 
intervillus space per villus unit of 7t(r22 - rf) where t2 is the outer radius of this annular 
cylinder and ri is the villus radius. This model allows for diffusion of capric acid, the 
complexes, and HPB in the aqueous phase (ABL and intervillus space), rapid equilibrium 
between capric acid and HPB, and absorption of neutral free capric acid across the 
biomembrane at the various surfaces (i.e., tip, lateral surface, and crypt) of the villi into a 
blood sink. The villi density is the number of villus units per cm of flat surface area and 
the cross-sectional area of the average intervillus space is the total intervillus cross-
sectional area per cm2 of flat surface divided by the villus density. 
Although previous researchers have used similar villus models to demonstrate the 
effects of the villus geometry on drug absorption,24"26 this study was to examine for the 
first time the concept that including a cyclodextrin in the formulations may increase the 
effective epithelial surface area utilized for absorption of highly lipophilic molecules by 
providing a means for the permeant to diffuse further into the intervillus space than 




















Fig 4.1 Schematic representation of the villus model (VM). Parameter values are listed 
in Table 4.2 
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Table 4.2 Parameters of the villus model 
Aqueous boundary layer thickness 0.117 cma 
Villus height (hv) 0.0399 cmb 
Villus radius (r^ 0.0037 cmb 
Radius of villus plus intervillus space radius (r2) 0.0049 cm 
Villus density 1.32x104 villi per cm2 of flat surfaceb 
Cross-sectional area of average intervillus space0 3.24x10 5 cm2 per villus; area=rc(r22-r12) 
a
 determined in the present study 
taken from reference26 
c






Fig 4.2 Boundary conditions for the COMSOL finite-element villus model simulations, 
where ri is the villus radius, r2 is the radius of the villus plus the associated intervillus 
space, and hy is the villus height. 
Table 4.3 Definition of boundary conditions for Fig 4.2 
Site Boundary conditions 
Luminal solution: caprate-HPB solution with total caprate at 
J 0.054 mM and HPB from 0-50 mM 
_2 Axis of symmetry 
3> 4, ^ The local capric acid flux, j , = PjCJ! where Pi (Pj=Pi,vM) is the 
intrinsic membrane permeability coefficient of capric acid and 
CI is the villus surface site concentration of free capric acid 
species 
_6 Impenetrable boundary, capric acid flux, j , =0 
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effectively utilized is dependent on the various parameters (Table 4.1) and the 
experimental conditions, these including the intrinsic bio-membrane permeability 
coefficient (PJ,VM), the aqueous diffusion coefficients, the HPB concentration, and the 
binding affinity of the permeant to HPB. 
To put the respective surface area contributions into proper context, we define the 
surface area ratio, RVM/FSM, by 
RVM/FSM = AVM/AFSM (4.2) 
where AVM and AFSM are the surface areas of an ileal segment for the VM and the FSM 
cases, respectively. For an ileal segment of length (1) = 10 cm and radius (r) = 0.2 cm, 
AFSM, is 
AFSM = 27trl = 12.6 cm2 (4.3) 
AVM for the same ileal segment is 
AVM = AUp + A ^ + Acrypt (4.4) 
where AtiP, ALS, and Acrypt are the area contributions from the villus tip, lateral surface, 
and the base of the crypt, respectively, and the values for these calculated from the 
parameters given in Table 4.2 are presented in Table 4.4 along with the RVM/FSM values. 
It is seen that full access to all area contributions in the VM may yield a maximal surface 
area advantage over the FSM by a factor of RVM/FSM =13.3. 
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Table 4.4 Maximal surface area contributions in the VM 
of the rat ileum 
VM/FSM Villus Surface Percent of R 
site area (cm2) villus area by location 
Tip 7.2 4.3% 0.57 
Lateral surface 154.5 92.4% 12.30 
Bottom (crypt) 5A 3.3% 0.43 
Total area 167.1 100% 13.30 
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4.3 Materials and Methods 
4.3.1 Chemicals and reagents 
For the in situ single pass perfusion system, the phosphate buffer solution 
consisted of 57 mM NaH2P04H20 and 79 mM Na2S04. The pH was adjusted to 7.4 
with 10 M NaOH. Capric acid was obtained from Sigma-Aldrich (St. Louis, MO), 
[14C]Mannitol, [14C]capric acid, and [14C]sodium taurocholate were purchased from 
Moravek Biochemicals Inc. (Brea, CA). Hydroxypropyl-p-cyclodextrin (Kleptose HPB) 
was obtained by a generous gift from Roquette America (Keokuk, IA). The purity of the 
radioisotopes was checked using high pressure liquid chromatography and found to be 
>97% pure. Solvable tissue solubilizer and Ultima Gold scintillation cocktail were 
obtained from PerkinElmer (Boston, MA). Other chemicals were of reagent grade. 
4.3.2 In situ single pass perfusion experiments 
The procedures used for the single pass perfusion experiments followed the 
procedures used by Tsutsumi et al. with some modifications. Male Sprague-Dawley 
rats weighing 300-400 g for intestinal perfusion, or retired breeders for blood donation, 
were obtained from Charles River (Wilmington, MA) and were used under the approval 
of the Institutional Animal Care and Use Committee at the University of Utah. The 
animals had free access to food and water prior to the experiment. The animal was 
placed in an anesthesia chamber and administered 5% halothane in oxygen at 1 L/min 
until unconscious. It was then transferred to a 37°C circulating water heating pad and 
administered 2% halothane in oxygen at a flow rate of 1 L/min through a small animal 
nose cone throughout the duration of the surgery and experimental setup. After testing 
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the animal for responsiveness using the foot pinch method, a 5 cm long silastic cannula 
was implanted into the jugular vein for blood collection or blood infusion as the case may 
be. In the case of blood donation rats, 1 ml of heparin solution (1000 U/ml) was infused 
into the animal via the jugular cannulation at a rate of lml/min. The pump was then 
reversed and the blood was withdrawn into a vial at the same rate until the animal 
expired. The vial was previously rinsed with dilute (100 U/ml) heparin, and 1ml of dilute 
heparin in saline was added to every 10 ml of blood to prevent clotting. The blood from 
these donor animals was used to replace the blood collected from the mesenteric vein of 
perfusion experiment animals. For the case of perfusion experiment rats, the jugular vein 
was cannulated as described above and the ileum was cannulated as follows. A 6 cm 
midline incision was made from the supralumbar to the sternum, and the distal ileum was 
located using the ileocecal junction as the point of reference. An approximately 10 cm 
segment of distal ileum was selected such that the entire mesenteric venous cascade from 
this intestinal segment drained into a single vein and all the blood from this segment 
could be collected by cannulating this vein. A semicircular incision was made at each 
end of the isolated segment of the ileum using electrocautery, and the luminal contents 
were removed by rinsing the lumen with isotonic saline at 37°C. A kynar reducing 
connector (from 3/32 inside diameter to 1/16 inside diameter, part number C1.5-1NK, 
Eldon James Corp., Loveland, CO) was then inserted into the incision at each end of the 
ileal segment and ligated using 4-0 silk suture. After testing to make certain there were 
no leaks of perfusion solution and then displacing any air bubbles trapped in the isolated 
ileal segment with saline, the proximal cannula was connected to a 60 ml syringe 
containing the perfusion solution and mounted in a perfusion pump. The distal cannula 
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was connected to tubing that was mounted 7 cm above the bench surface. This slight 
elevation prevented the lumen from collapsing but did not distend it. Following the 
intestinal cannulation, the connective tissue surrounding the previously selected 
mesenteric vein was gently removed using forceps. A 4-0 silk suture was carefully 
passed below the mesenteric vein, making sure the suture passed between the mesenteric 
artery and the mesenteric vein such that when the cannula to be placed in the mesenteric 
vein was ligated, the blood flow from the mesenteric artery was not disrupted. The 
mesenteric vein was cannulated using a 24 gauge Angeocath catheter (Beckton 
Dickenson, Sandy, UT), such that only the top 1cm tip remained in the vein. This 
cannula was then secured in place by the previously placed 4-0 silk suture. A 50 cm 
silastic tubing (.025 in. ID x .047 in. OD) previously rinsed with dilute heparin was then 
carefully connected to the mesenteric vein cannula for blood collection. This tubing 
draped over the bench so that the end of the tubing was 20 cm below the bench surface. 
After blood collection from the mesenteric vein was established, previously collected 
donor blood (at 37°C) was infused into the jugular vein of the rat at a rate equal to the 
blood collection rate from the mesenteric vein cannulation. Then the intestinal perfusion 
was initiated (perfusion rate 0.2 ml/min) and the intestinal segment and venous cascade 
were covered with 2 pieces of 3-ply gauze (4 in. square). The halothane concentration 
was then reduced to 0.5% for the duration of the experiment. For capric acid with or 
without HPB, the perfusion solution consisted of 0.2-0.6 (xCi/ml [14C]capric acid, 0.05 
mM cold capric acid, and an appropriate amount of HPB in the pH 7.4 buffer. The final 
osmolarity of the buffer was adjusted to 300 ± 10 mOsm/kg using reagent grade Na2S04, 
and the final ionic strength was 0.37. Taurocholate experimental buffer solutions were 
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prepared in the same manner except the buffer contained only [14C]taurocholate (no cold 
taurocholate or HPB). Each formulation was perfused through the rat ileum at 0.2 
ml/min using a model 100 perfusion pump (KD Scientific, Holliston, MA). The animal 
was kept at 37 ±1°C using a circulating water blanket, and the perfusate temperature was 
30 ±2°C. The perfusate was collected at 10-minute intervals using preweighed 20 ml 
scintillation vials. Perfusate samples were weighed to determine the perfusion outflow 
rate, and a 100 |il sample of perfusate was assayed via scintillation counting to determine 
the permeant concentration in the perfusate. Water absorption/secretion was determined 
to be less than 5% by comparing the outflow of the perfusion solution with the inflow. 
The osmotic pressure change of the solution was found to be less than 5% from periodic 
osmolarity determinations using a micro osmometer (model 3300 Advanced Instruments 
Inc. Norwood, MA). Mesenteric blood flow from the isolated intestinal segment was 
collected at 10 minute intervals in preweighed 20 ml scintillation vials. The vials were 
weighed and the blood was analyzed using the following method. Exactly 500 JLLI of 
whole blood was pipetted into a fresh 20 ml scintillation vial along with 100 ul of heparin 
(5000 units/ml) and 550ul of tissue solubilizer and incubated for 1 hour in a 50°C 
shaking water bath. Then 100 |il of 100 mM of EDTA at pH 7.4 and 300 ul 30% H202 
were added to the sample and incubated at 50°C for another hour. The sample was then 
mixed with 10 ml scintillation cocktail and assayed by scintillation counting. For each 
experiment, an additional 500 |il sample of whole blood was taken from the 10 minute 
time point and spiked with 100 (j,l of donor solution and then analyzed as above as an 
internal standard to correct for any quenching due to the blood or reagents. The DPM of 
the 10-minute sample alone was subtracted from the internal standard and the remaining 
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DPM were compared to 100 ul of donor solution in saline. The internal standard DPM 
was generally within 10% of the saline DPM. The blood samples were corrected by 
multiplying the blood DPM by the ratio of saline donor DPM to internal standard DPM. 
At the end of the transport experiment, the length of the intestinal segment was measured 
with silk thread. The outside diameter and intestinal wall thickness of the ileum were 
measured using a micrometer to determine the inside radius of the ileum. These 
measurements were used to calculate the flat surface area (AFSM) of the ileum. 
4.3.3 Villus model simulations 
Finite-element simulations of permeant diffusion across the ABL and into the 
intervillus space with drug absorption into a sink at the villus surface sites were 
performed with computer software FEMLAB (v3.0a, COMSOL, Inc. Burlington, MA). 
The steady state diffusion analysis and 2D axial symmetry were used to model permeant 
absorption across the surfaces of a single villus in the rat ileum. Fig 4.1 depicts a 
schematic of the idealized villus structure. The villus height, radius, and intervillus space 
were obtained from Oliver et al.26 and are listed in Table 4.2. The boundary conditions 
are described by Fig 4.2 and Table 4.3. Other parameters used in the VM calculations 
are listed in Table 4.2. As shown in the previous chapter, the diffusion coefficients of the 
free caprate ion (A-) and the free capric acid (HA) species are essentially the same, as are 
the diffusion coefficients of the A~»HPB and HA*HPB complexes. The diffusion 
coefficient of the free HPB (HPBf), which was not experimentally determined in this 
study, was assumed to be the same as that of the complexes. The value for the diffusion 
coefficient of HPBf was shown from model calculations to be inconsequential within a 
factor of ±2-fold because HPBf is not absorbed and because the HPBf concentration was 
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at least 10 times greater than those of either of the complexes. The axis of symmetry of 
the villus allows us to describe the system in two dimensions (height, z, and radius, r,) 
such that for a given r and z the species concentrations at steady state are identical for all 
angles (cp). Free capric acid is absorbed into a sink at the top, sides, and bottom of the 
villus structure. The simulation assumes rapid equilibrium between all species (i.e., HA, 
A", HPBf, HA«HPB and A~«HPB; pH constant at 7.4): 
A " + H P B f ^ _ A « H P B 
HA + HPBf ^Z!HA • HPB 
H A 7 ^ H + + A " 
where the forward and reverse reaction rate constants ki, k2, kj, and k4 are arbitrarily 
chosen high enough that all species are in rapid equilibrium (as examples ki= 1x10 mM" 
V1, k2= 4xl05 s'1, and K" = ^ - = 2.5 mM_I; k3= 7.5xl06 mM"Y\ Lt= lxlO6 s'1, and 
k2 
Ku = — = 7.5 mM-1). At steady state, the condition expressed by Eq (4.5) must apply 
k„ 
simultaneously for all species. 
—^ = V-(D iVC i) + R = 0 (4.5) 
3t 
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where Q represents the concentration of each species and Dj represents the diffusion 
coefficient of each species . V is the standard del (nabla) operator for cylindrical 
coordinates, and R is the rate of formation or disappearance of either complex and of 
either A - or HA: 
R=-k1[A"][HPB] + k2[A"«HPB] (4.6) 
R = -k3[HA][HPB] + k4[HA»HPB] (4.7) 
The local capric acid flux (j) at any villus site is expressed as 
J = Pi,vMCs (4-8) 
where Pi,vM is the villus model intrinsic capric acid membrane permeability coefficient 
and Cg is the villus surface site free capric acid concentration. It is to be noted that, 
from here on, P;;VM will represent the P; for the VM and PI,FSM that for the FSM. 
4.3.4 Treatment of experimental data using the FSM 
Here we describe the application of the flat surface model (FSM) in the analysis 
of 14C-capric acid absorption in the in situ single pass perfusion experiment, following 
1 ft 
the method and conventions of Tsutsumi et al. The isolated ileum segment is taken as a 
smooth, hollow cylinder, with the perfusing solution from the reservoir entering the 
proximal intestinal segment at x=0 and exiting the segment at x=l. Fig 4.3 is a schematic 
representation of the intestinal perfusion experiment where r and 1 are the inside radius 
























































































































































































across the absorptive surface of the ileum, there will be a steady-state longitudinal 
concentration gradient down the lumen of the isolated segment.27 The logarithmic mean 
permeant concentration in the lumen, <C>, is taken as the effective concentration of 
capric acid in the lumen. 




where C(0) is the inflow total concentration of total caprate at x=0 and C(i> is the outflow 
total concentration of total caprate at x=l. 
The total permeability coefficient (PT) is then calculated from 
J 
P T = 2— (4.10) 
T
 2m-l<C> 
where Jb is the average steady-state flux of the permeant appearing in mesenteric blood. 




 1 (4.H) 
+ • 
peff p 
rABL r i r . 
where Pm is the effective membrane permeability coefficient and P^L is the effective 
permeability coefficient in the aqueous boundary layer. In the case of the present study, 
only free unionized capric acid (HA) is assumed to be absorbed; therefore, Eq (4.11) 
becomes: 
I l l 
P T = - I j — (4-12) 
— 5 - + 
peff p pu 
rABL r i ,FSM 1 
where PJ,FSM is the intrinsic membrane permeability coefficient of HA and Fu is the 
fraction of the total caprate in the HA form at the membrane-ABL interface. Since 
>eff D 
eff 
PIBL = . Ecl (4-12) becomes 
hABL 
P T = T : (4.13) 
h A B L . + 1 
Deff P Fu 
Also, 
Deff =D fF f+D*F* (4.14) 
where Deff is the effective aqueous diffusion coefficient of total caprate in the 
caprate/HPB solution system, hABL is the thickness of the aqueous boundary layer (ABL), 
Df is the diffusion coefficient of HA and A" (6.9 xlO"6), D* is the diffusion coefficient of 
HA-HPB and A" »HPB (2.9 xlO"6), Ff is the fraction of free caprate (HA + A"), and F* is 
the HPB-bound fraction of caprate (HA«HPB and A - *HPB). It was previously validated 
that the diffusion coefficients of HA and A" are essentially the same and that the 
diffusion coefficients of HA»HPB and A~ »HPB are the same within experimental error 
(Section 3.5.1.3). 
It is of interest to point out that another method often used for calculating Pj from 
experiments such as in the present study involves the following equation23'28 
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P T = - ~ j l n [ c ( 1 ) / C ( 0 ) ] (4.15) 
where Q is the steady-state intestinal perfusate flow rate (cm3/s) and the other terms are 
already defined. PT calculated from Eq 4.15 is based on the fraction of permeant 
remaining in the intestinal segment at x=l. For the present in situ system we have a 
relatively short intestinal segment length, a relatively large ABL thickness, and relatively 
low diffusion coefficients. In this case, it is easy to anticipate that Q/Co would be in the 
range of 0.7 to 0.9 with most of the results in the range of 0.8 to 0.9. For this situation, 
the uncertainties and errors in the calculation of Pj based on Eq 4.15 are expected to be 
up to 10 times greater than the PT values calculated from Eq 4.10. For this reason, PT 
results based on Eq 4.15 are not discussed here. A summary of an analysis of the PT 
values based on Eq 4.15, however, is presented in Appendix A of this chapter. 
4.4 Results and Discussion 
4.4.1 Intestinal absorption 
Fig 4.4 shows typical experimental results of the fractions of [14C]-capric acid 
remaining in the ileal segment of length -10 cm, C(i> / C(0), in the absence and presence of 
50 mM HPB. Here, in 20 minutes Qi) / C(0) is seen to attain steady-state values of 0.7 and 
0.9 in the absence and presence of 50 mM HPB, respectively. Fig 4.5 shows the 
cumulative amounts of [14C]caprate transported into the blood for examples of caprate 
alone and caprate plus 50 mM HPB. Consistent with the results of Fig 4.4, these data 
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O 0.05 mM Capric acid with 50 mM HPB 
• 0.05 mM Capric acid alone 
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Time (min) 
40 50 60 
Fig 4.4 Representative plots of the fraction of caprate remaining in the intestinal 
lumen (Qi/Qo)) for each 10 minute sample for capric acid alone (8.8 cm gut 
length) and capric acid in the presence of 50 mM HPB (10.0 cm gut length). 
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O 0.05 mM capric acid with 50 mM HPB 
• 0.05 mM capric acid alone 
-9-
10 20 30 40 50 60 
Time (min) 
Fig 4.5 Representative plots of cumulative caprate appearance in blood as a function 
of time for capric acid alone and capric acid in the presence of 50 mM HPB. Note 
steady-state of absorption was reached in both cases in around 20 minutes. 
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and was essentially independent of the HPB concentration. The perfusion rate, the blood 
flow rate, and the osmotic pressure of the solution in the intestinal lumen were generally 
constant during an experiment and did not vary greatly from run to run (Figs 4.6 and 4.7). 
Water absorption/secretion was ±5% and inconsequential. Figs 4.4 to 4.7 represent 
typical displays from absorption studies conducted with 0.05 mM capric acid in HPB 
concentrations from 0 to 50 mM (i.e., molar ratios of [HPB]/[HA] ranging from 0 to 
1000:1). Similar patterns as seen in Figs 4.4 through 4.7 were also observed in the 
[14C]taurocholate experiments conducted with phosphate buffer at pH 7.4. Table 4.5 
summarizes the flux of capric acid, the mean luminal concentration and the total 
permeability coefficient (calculated using Eq 4.10). 
4.4.2 Analysis of the experimental PT data 
with the flat surface model (FSM) 
The principal outcomes of the FSM analysis of the experimental results are 
presented in Table 4.6 and Fig 4.8. The experimental PT values (column 3 of Table 4.5) 
was best-fitted to Eq 4.12 in the following manner. As it was apparent from a 
preliminary analysis that, at low HPB concentrations (<3.0 mM), capric acid absorption 
would be essentially 100% ABL controlled, a first approximation for the best IIABL value 
was obtained based on this consideration. Then a first approximation of a best-fit value 
for Pi,FSM was found using only the PT results from the three highest HPB concentration 
experiments. Subsequent iterations employing all of the data did not significantly change 
these results. The best-fit IIABL and PJ,FSM values at the three lowest HPB concentrations, 
and the individual PI,FSM values at the three highest HPB concentrations are all presented 
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40 50 60 
Fig 4.6 Intestinal perfusate flow rate of 14C-caprate solution and blood flow rate out 
of the cannulated mesenteric vein for each 10 minute sample period. Data are from a 
typical experiment of 50 mM HPB. 
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10 20 30 40 
Time (min) 
50 60 
Fig 4.7 Representative plot of periodic determination of the osmolarity (mOsm/kg) 
of the perfusate from a typical experiment with caprate plus 50 mM HPB. The 0 
minute time point represents the stock donor osmolarity. 
Table 4.5 Experimentally determined flux (Jb) and total permeability coefficient 
(PT) for caprate transport across the rat ileum in the presence or absence of 





















2.88 (± 0.69) 
1.85 (± 0.35) 
1.45 (±0.16) 
1.07 (± 0.24) 
1.01 (± 0.22) 
0.78 (± 0.25) 
PTx105 
(cm/s) 
5.50 (± 0.48) 
5.76 (± 1.37) 
3.69 (± 0.70) 
2.89 (±0.31) 
2.14 (±0.49) 
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0 1 10 
[HPB] mM 
100 
Fig 4.8 Comparison of experimental PT values with FSM predictions. The solid curve 
depicts the best-fit FSM results employing the FSM-model parameters of Table 4.1. The 
dashed curve represents PT values if 100 percent ABL-controlled over the entire range. 
121 
variability and good consistency with the reference value obtained with 
[14C]taurocholate. The individual PJ,FSM values show greater variability, as was expected. 
The capric acid absorption for the three highest HPB cases was still 78 to 59 percent 
ABL-controlled and was therefore still relatively insensitive to Pi,FSM- The large 
variability in the individual PI.FSM values also obscures any indication of a trend in PJ,FSM 
with increasing membrane-controlled capric acid absorption (that would have been 
expected as discussed later in the villus model analysis). Nonetheless, the experimental 
PT values correlate with the FSM deduced values reasonably well (see Fig. 4.8) 
In applying the FSM it was assumed that the ABL can in fact be treated like a 
stagnant layer and that molecules cross the ABL by molecular diffusion only. It is 
important to note that all of the IIABL values listed in column 6 of Table 4.6 are essentially 
the same within the data scatter while Deff varied by almost a factor of two. This 
evidence supports the assumption implied in Eq (4.12) that the ABL can be treated as a 
stagnant diffusive layer for the molecules in the present study. If the ABL were to be 
characterized by a significant contribution from convective diffusion, the IUBL 
determined would have been expected to have a dependence upon the diffusion 
coefficient to the nth power (Dn)29"31 where n may be a fraction greater than zero. 
Although the experimental error in the IIABL values is too large to definitively state that 
there is no significant amount of convective diffusion in the ABL, the results suggest that 
transport across the ABL is predominantly diffusion-controlled and that convection does 
not contribute significantly to overall transport across the ABL, this supporting the 
appropriateness of the stagnant layer assumption inherent in Eq (4.12). 
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It is of interest to note that the PJ,FSM for capric acid has been found to be 5-6 
orders of magnitude larger than the PABL; this is why absorption of capric acid from a 
solution of capric acid species alone would be essentially completely insensitive to Pi,FSM-
At high HPB concentrations and a high pH of 7.4, however, Fu is sufficiently small that 
the product of PI,FSM and Fu is comparable to PABL; this then affords reasonable sensitivity 
to PJ,FSM (see Eq 4.12). This example illustrates that, although lipophilic weak acid 
molecules can have a very high intrinsic membrane permeability coefficient compared to 
the aqueous boundary layer permeability coefficient, by reducing Fu sufficiently (i.e., 
high HPB and high pH) an accurate P^FSM determination may be possible. This also 
illustrates the important role played by HPB in obtaining PI,FSM values under 
experimental conditions that otherwise would have been insensitive to PJ,FSM- This role 
of cyclodextrins and other carriers to improve sensitivity of the determination of Pi,FSM 
for lipophilic molecules has not, to our knowledge, been previously reported. 
At this point it should be helpful to comment on the reasonableness of the 
intrinsic permeability coefficient deduced from the FSM (PJ.FSM), particularly in light of 
the large error bars (see Fig 4.8). An attempt can be made to examine the consistency of 
the Pi,FSM value of 3.5 in Table 4.6, column 8 with data from the work of Ho et. al. who 
had obtained permeability coefficients of a series of n-alkanoic acids up to n-octanoic 
acid employing a modified Doluisio in situ technique using rat jejunal segments. By 
extrapolation of the shorter chain fatty acids, N. Ho has deduced a PJ,FSM value for capric 
acid absorption in the rat jejunum (unpublished results) that appears to be within a factor 
of two of the PI,FSM value for capric acid transport in the ileum after the above 3.5 cm/s 
value is corrected for a) the effect of the presence of HPB and b) the effect of the 
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differences between the ileum and jejunum villus architecture. Details are presented in 
Appendix B. The closeness of the PJ,FSM values for the ileum and the jejunum seems 
reasonable in light of the known constituent compositions of the ileum and the jejunum, 
especially those components associated with the lipoidal structures. 
A final point of interest is that the goodness of fit of the FSM to experimental data 
(see Fig 4.8) provides an opportunity to examine the effects of HPB on the transport 
behavior of capric acid for equal thermodynamic activity of capric acid in the lumen (for 
example, as would be the case for considering saturated solutions of capric acid in the 
lumen; this consideration should be important in the formulation optimization of very low 
solubility lipophilic drugs). Fig 4.9 shows that the capric acid activity would drop by 
98.9% across the ABL for the capric acid alone case compared to a 59.2% drop for the 
capric acid plus 50 mM HPB case. This would translate into a 37-fold increase in the 
surface thermodynamic activity (and therefore the flux) of capric acid in the presence of 
50 mM HPB compared to the capric acid alone condition for equal capric acid 
thermodynamic activity conditions in the lumen. Fig 4.9 demonstrates that the HPB as a 
drug carrier can improve bioavailability for lipophilic permeants by increasing the 
surface thermodynamic activity of the permeant at the membrane surface by reducing the 
permeant concentration gradient across the ABL (See also Fig 3.8). 
4.4.3 Analysis of the experimental results 
with the villus model CVM) 
The villus PJ,VM values were deduced using the database of the fluxes of capric 
acid at 10, 30 and 50 mM: the kinetics are partially membrane-controlled, the effective 
permeability coefficients of the ABL, where IIABL is 0.117, and the parameter values and 
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Fig 4.9 Relative concentration of total capric acid, expressed as a fraction of the luminal 
concentration, as a function of position in the ABL. 
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the conditions are given in Tables 4.1 - 4.3. The estimates of PJ,VM ranged from 0.39 to 
0.89 cm/s in the various cases (Table 4.7). The PJ,VM by least squares fitting was found to 
be 0.48 cm/s which is 7-fold smaller than the PI,FSM of 3.5 cm/s because of the differences 
in the effective absorptive surface areas utilized. The VM-deduced PT values are 
compared to experimentally determined values, and are presented in Fig 4.10. Model-
deduced PT values are found to be in good agreement with experimental Pj values for 
capric acid over the range of HPB concentrations studied with the model-deduced values 
falling within experimental error for all conditions. While the VM and the FSM both 
offer good predictability of PT for capric acid at pH 7.4 over the range of HPB 
concentrations studied, the following discussion presents some important insights that are 
revealed from the VM analysis that would not be discernable from the FSM. The surface 
area based on the VM parameters (see Table 4.4) is 13.3 times greater than the inside 
surface area of a smooth, hollow cylinder (the FSM). The extent to which capric acid 
may utilize this surface area in the presence and absence of HPB is illustrated in the 
concentration-distance profiles in Fig 4.11. It has been previously demonstrated25'26 and 
is widely understood that highly permeable compounds are absorbed primarily at the 
villus tips. As can be seen in Fig 4.11, the VM demonstrates that capric acid alone 
behaves like other rapidly absorbed, highly lipophilic compounds. For this case the 
concentration gradient of capric acid decays rapidly across the ABL, with only about 5% 
of the original lumen concentration remaining at the tips of the villi; as the capric acid 
reaches the villi it is rapidly absorbed at the villi tips, and the concentration decays 
rapidly to zero in the initial portion of the intervillus space. Because of the rapid 















































































































































































































































































Fig 4.10 Log plot of experimentally determined permeability coefficients (PT) for 
capric acid in the presence of 0-50 mM HPB. The solid line represents the best-fit 
VM results employing the VM-model parameters of Table 4.1. The dashed lines 
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Distance, cm 
0.12 0.14 
Fig 4.11 Fraction of total capric acid concentration versus distance across ABL and 
intervillus space. ABL thickness is 0.117 cm and villus height is 0.04 cm. Vertical line 
is ABL/villus tip interface, with the caprate concentration determined along a vertical line 
at the lateral villus surface extending upward to the ABL/lumen interface. 
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10% into the intervillus space, leaving the majority of the crypt cells un-utilized for 
absorption. With increasing HPB concentrations, however, the concentration gradient 
across the ABL is decreased. Additionally, more capric acid is able to penetrate further 
into the villus crypts. For the capric acid plus 50 mM HPB formulation, the total capric 
acid concentration at the tips is approximately 40% of that in the bulk, and the 
concentration at the bottom of the crypts is approximately one-half of the concentration at 
the tips of the villi. 
A comparison of the capric acid concentration distributions for capric acid alone 
and capric acid plus 50 mM HPB using iso-concentration profiles (representing total 
caprate, with a constant incremental concentration change between successive curves 
within the villus unit) provides further insight into the absorption characteristics of capric 
acid in the rat ileum (see Figs 4.12 and 4.13). The comparison of the two figures is 
striking with respect to the differences in the slopes of the iso-concentration lines at and 
around the villus tips. For the case of the capric acid alone conditions, one can see that 
the caprate iso-concentration lines for the 0 mM HPB case are much more horizontally 
parallel than those of the 50 mM HPB case just above the villus tip, demonstrating much 
more vertical diffusion, with a significant fraction of the caprate being absorbed by the 
villus tip; this is due to the higher Pm in the absence of HPB. For the 50 mM HPB case 
(Fig 4.13), the lines are more curved (more vertically inclined) just above the villus tip, 
demonstrating that the flux is directed more laterally (toward the intervillus space), 
resulting in a greater fraction of the caprate entering and diffusing down the villus crypt, 
this due to the lower Pm for the 50 mM HPB case. The result is more caprate in the villus 
crypt, allowing the HPB conditions to take fuller advantage of the available absorptive 
Distance from 
:he lumen/ABL 
















of the villous 
0.123 
* — 0.00385 





<i— 1.03 xlO"7 
Bottom of the villous crypt 
Fig 4.12 Iso-concentration profiles of caprate in the aqueous boundary layer and 
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Bottom of the villous crypt }„ 
Fig 4.13 Iso-concentration profiles of caprate in the aqueous boundary layer and 
in the intervillus space for the 0.05 mM caprate + 50 mM HPB condition. 
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surface area at the lateral surface of the villus. Also of note is the flux and concentration 
gradient within the intervillus space. For the case of the 0 mM HPB (Fig 4.12), the flux 
decays rapidly as demonstrated by the rapidly increasing space beween successive iso-
concentration lines. This is consistent with the rapidly decaying caprate concentration 
seen in Fig 4.11 for the 0 mM case. Additionally, in the 0 mM HPB case there is an 
observable lateral concentration gradient within the intervillus space of about 5% from 
the middle of the intervillus space (far right side of the figure) to the lateral surface of the 
villus, this due to the absorptive surface of the villus. For the 50 mM HPB case, 
however, the flux decay in the intervillus space and the lateral concentration gradients are 
much less pronounced. This result was expected due to the carrier effect of the HPB 
present in the intervillus space, this providing the means for greater access of caprate to 
the lateral surfaces of the villus. Taken together with the VM, Figs 4.12 and 4.13 
demonstrate that HPB acts as a carrier molecule for caprate not only across the ABL, but 
also into the intervillus space, allowing capric acid to more effectively access and utilize 
the surface area available for absorption. 
A permeant's ability to access the various surface sites of the villi has been 
defined by Winne and applied by Oliver et al., and it has been given the term 
accessibility. Accessibility is a means to quantify the extent to which a permeant utilizes 
the surface area available and is calculated by dividing the actual flux (Jactuai) of the 
permeant by the flux that would occur if the surface concentration of the permeant was 
constant for all regions of the villi i.e., tip, lateral surface, and crypt (Jsc.constam)- Jsc,constant 
is determined by: 
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•* SC.cons tan t = ^vm "i.VM^s.tip (4.16) 
where AVM is the villus surface area (see Eq 4.4), C"ti is the free capric acid species 
concentration at the villus tip, and PJ.VM has been already defined. Jactuai is the VM 
calculated flux. Accessibility was calculated for all the capric acid/HPB solutions using 
the VM (see Table 4.7, column 6). A comparison of the accessibilities for the different 
capric acid formulations quantitatively demonstrates what is already qualitatively 
understood from Figs 4.11, 4.12, and 4.13: that HPB improves the access of capric acid to 
the surface area in the villus crypts. For the case of the 50 mM HPB formulation, capric 
acid is able to access 4.5-fold more surface area than the capric acid alone formulation. It 
should be noted that accessibility increases with increasing concentration of HPB, and 
that 50 mM HPB allowed access of capric acid to slightly more than one-half of the total 
surface area available for absorption. 
Additional insight is available from the accessibility value when we compare the 
VM to the FSM. The VM has 13.3 times more surface area than the FSM. Therefore, if 
we multiply the accessibility value determined from the VM by its surface area 
amplification factor (13.3), we can see how much surface area is effectively utilized for 
absorption as compared to the flat model (see Table 4.7). Making this comparison 
demonstrates why the PJ,VM values obtained from the VM and the FSM differ by a factor 
of approximately 6. Column 7 in Table 4.7 shows that the more membrane-controlled 
conditions utilize much more surface area than would be predicted from the flat model. 
Several investigators32"34 have pointed out that the effective ABL thickness in 
anesthetized animals may be much thicker than in unanesthetized animals due to the 
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influence of the anesthesia upon the intestinal motility. Yuasa et al.35 reported a 2- to 3-
fold thicker ABL thickness in anesthetized rats compared to unanesthetized rats in studies 
using a single pass perfusion technique with a flow rate of 0.16 ml/min in the rat jejunum. 
In order to examine how this may impact upon the principal conclusions of this chapter, 
caprate transport was also modeled with the VM under the condition where the IIABL 
value was reduced 10-fold from 0.117 cm to 0.0117 cm (10-fold is much greater than that 
indicated in the study by Yuasa et al.35). The VM simulation of capric acid concentration 
as a function of distance as with varying concentrations of HPB demonstrated that, as 
expected, each condition was more membrane-controlled than its counterpart with the 
thicker IIABL (compare Figs 4.14 and 4.11). It is quite noteworthy that even for a very 
thin IIABL condition the intervillus concentration of caprate and the accessibility of caprate 
to the membrane surface sites also increased significantly with increasing concentration 
of HPB. This exercise of comparing the thicker IIABL results encountered in in situ 
experiments (Fig 4.11) to a thinner hABL expected in vivo (Fig 4.14) demonstrates that 
even for in vivo conditions the hABL is likely a significant transport barrier for highly 
permeable molecules such as capric acid. Additionally, this exercise shows that a carrier 
molecule such as HPB can markedly improve the membrane accessibility of rapidly 
absorbed compounds under in vivo conditions. This increased accessibility may become 
particularly useful when the molecule of interest is a membrane permeability enhancer 
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Fig 4.14 Fraction of total caprate concentration versus distance across the ABL and in the 
intervillus space, when IUBL = 0.0117 cm ; all other parameter values are the same as in 
Fig 4.11. The vertical line is the ABL/villus tip interface. 
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4.4.4 A comparison of the villus model 
(VM) to the flat surface model (FSM) 
With respect to the goodness of fit of experimental data to model-predicted PT 
values, the VM and the FSM models both predict PT equally well. In light of the 
discussion above, however, the VM clearly provides additional valuable information 
concerning the intrinsic permeability coefficient values, effective surface area utilized for 
absorption, and extent of permeant penetration into the villus crypts. Although it is well 
understood that the small intestine contains villi which significantly increase the effective 
surface area available for absorption , the common approach for predicting permeability 
across the membranes of the small intestines simplify the gut as a hollow, smooth 
cylinder. The VM, however, utilizes a better first approximation to the morphology of 
the absorptive surface of the small intestine than does the FSM. In addition to the 
visually apparent differences between a smooth cylinder and the small intestine, there is 
also experimental evidence that the villus structure can play an important role in the 
presentation of chemical absorption enhancers to the absorptive surfaces of the small 
intestine. Utilizing capric acid as an enhancer for mannitol absorption in the rat ileum, it 
was found (see Chapter 5) that in the presence of 30 mM HPB a three- to four-fold higher 
capric acid flux is observed before any indication of mannitol permeability enhancement 
is seen as compared to capric acid alone. This experimental evidence suggests that a 
significantly greater surface area is effectively utilized for capric acid absorption in the 
presence of 30 mM HPB; this is consistent with the VM, but not with the FSM. For the 
above stated reasons, the VM appears to be a more useful model for quantitatively 
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investigating the effects of carrier molecules on the effectiveness of chemical enhancers, 
such as capric acid, on absorption rates of polar molecules in the small intestine. 
4.5 Significance 
The effects of HPB upon the absorption of a lipophilic permeant in the rat ileum 
were observed in this study, and the means for a quantitative interpretation of these 
effects have been presented. The VM and FSM demonstrated that HPB reduces the 
concentration gradient of the permeant across the ABL from the lumen to the membrane 
surface and increases the small intestinal membrane surface area utilized for absorption 
by allowing the permeant to penetrate deeper into the intervillus space and access 
additional surface area within the villus crypt that would otherwise would not have been 
available for absorption. Taking both of these effects into consideration, HPB has the 
potential to significantly increase the permeant flux in the ileum (for constant free 
permeant lumen concentration comparisons). That cyclodextrins can be effective 
absorption enhancers through their roles as carriers for high lipophilicity low solubility 
(BCS class 2) compounds has been previously demonstrated by others on a qualitative 
basis. The contribution of the present study has been to demonstrate the mechanism of 
absorption enhancement using the physical model approach and to experimentally test the 
model predictions employing capric acid as the highly lipophilic, ionizable permeant and 
HPB representing a cyclodextrin carrier molecule. The physical model approach utilized 
in this study has also demonstrated the complex interplay of key parameters and their 
relative contributions to overall permeant flux. An obvious practical application of this 
study would be in the use of the VM for predicting the optimum composition of 
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cyclodextrin-containing formulations for the oral administration of highly lipophilic drug 
molecules. 
4.6 Appendix A 
4.6.1 Analysis of the PT results based on Eq 4.15 
For reasons given in Section 4.3.4, no attempt has been made to include PT values 
(PT=PT,C) deduced from Eq 4.15 for discussion. Here, we present the Px,e results and a 
brief summary of the impact of these results upon the conclusions in this chapter. It is to 
be noted that, for this appendix, Px>e is to represent PT deduced from Eq 4.15 and Pi,b that 
deduced from Eq 4.10 
Table 4.8 shows all of the relevant experimental data and the results of the 
analysis. An initial concern was the large differences between the Pj.b and Px,e values 
(column 9). It was apparent, however, that an approximately 10% adjustment in the ratio, 
C(i/C(o), was sufficient to yield PT values for which PT,b = PT> Importantly, this 
adjustment corresponded to an average change in PT b of only 7%, which is well within 
the data scatter and would not significantly impact upon the conclusions of this chapter. 
Because these discrepancies, though small, appeared to be systematic, further 
tests were conducted with the syringe and polymer tubing system to determine whether 
any significant unexpected time dependences of glass or tubing adsorption might have 
occurred. It was determined from these additional experiments that there was no 
significant change in solution inflow concentration (C(o>) as a function of time during the 
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4.7 Appendix B 
4.7.1 Calculation permitting the comparison of 
capric acid absorption data in the ileum 
with jejunum data from Ho et al.37 
The purpose of this appendix is to examine whether the capric acid value of 3.5 
cra/s deduced with the FSM in the present study is consistent with a PJJSM value of 1.2 
cm/s obtained by Ho et al. for capric acid absorption in the rat jejunum. Ho et al. 
investigated a series of n-alkanoic acids (butanoic to octanoic) employing a modified 
Doluisio in situ technique and deduced the capric acid PJ,FSM value for the jejunum by 
extrapolating the PJ,FSM data of the shorter chain fatty acids to carbon number often. The 
authors also showed that Pp0re, the pore pathway (paracellular pathway) permeability 
coefficient was negligible in the pH range 6-7, for the longer chain fatty acids (including 
capric acid); therefore, PJJSM of the longer chain fatty acids should be predominantly a 
measure of the transepithelial transport (lipoidal pathway). 
A) to make this comparison, because in the present study the PJ;FSM value of 3.5 
was deduced in the presence of HPB, a correction for the effect of HPB upon PJJSM must 
be considered. This correction is simply correcting for the accessibility ratio 
corresponding to the particular HPB concentration relative to the OmM HPB 
concentration using the villus model (see Table 4.7). Let us take the specific case of 50 
mM HPB, for which the accessibility ratio is 4.48. Hence 
3.7 
Pi FSM = ~0.8 cm/s 
4.48 
143 
forOmMHPB. Let us call this Pi,FSM,iieum-
B) Secondly, a "correction" for the differences in the villus unit geometry 
between that of the ileum and that of the jejunum must be considered in order to obtain 
the corresponding PJ.FSM value for the jejunum (i.e., the Pi,FSM,jejunum) from 
*i,FSM,ileum-
This will require the use of the villus model. The geometrical dimensional values for the 
jejunum and the ileum are given by Table 4.9 and the areas corresponding to the various 
sites of the villus architecture are presented in Table 4.10. The strategy entails using the 
P;,VM value obtained for the ileum in the present study together with the geometrical 
parameters of the jejunum (Table 4.9 and Table 4.10) to calculate the "corrected" 
Pi,FSM,jejunum value and then to see how close this value is to the Pi,FSM,jejunum value of Ho et 
al. Several calculational steps are involved. 1) The ileum PI.VM (0.48 cm/s; see Table 
4.1) is used in the VM together with the jejunum parameters (Tables 4.9 and 4.10) to 
obtain a model-calculated flux (J') of capric acid in the jejunum and a model-calculated 
free capric acid species concentration at the villus tip (C"tip) that together gives Jsc.constant 
(Eq 4.16). 2) Using the Jsc,constant and the J', we then calculate the accessibility (0.10) for 
capric acid in the jejunum from 
J' 
accessibility = (4.17) 
SC,cons tan t 
3) We now may calculate Pi,FSM,jejunum using the following equation, 
Pi.FSMjejunum = (accessibility)( AVM)(PI,VM) (4.18) 
Table 4.9 Geometric villus parameters of the ileum and the jejunum. 
From Oliver et al. 
Parameter Jejunum (ixm) Ileum (itm) 
villus radius (tip radius) 75 37 
radius of the intervillus space 7-20 (use 12) 12 
channel depth (villus height) 577 399 
values are in (im 
9 9 * 
Table 4.10 Intrinsic surface area (cm ) per cm of intestine. 
From Oliver et al. 














where accessibility = 0.10, AVM = 12.43 (Table 4.10), and Pi>VM = 0.48 (Table 4.1). Eq 
4.18 gives a Pi,FSM,jejunum value of 0.6 cm/s. This compares well with the 
"i,FSM,jejunum 
value of 1.2 cm/s of Ho et al. 
4.8 Glossary 
Definition 
aqueous boundary layer 
area of a smooth hollow cylinder for an ileal segment 
surface area of the villi (13.3 x the area of a smooth cylinder) 
area of the villus tip 
area of the villus lateral surface 
area of the villus crypt 
free caprate ion 
logarithmic mean concentration in the ileal segment 
inflow permeant concentration 
outflow permeant concentration 
concentration of the ith species 
total caprate concentration 
total free caprate concentration at the villus tip 
donor concentration at position X 
the villus surface site concentration of free capric acid 
the adjusted C(i/C(o) ratio that will give PT= P'T,b=P'T,e where 
P'x,b and P'-r,e are the adjusted new values for PT based on Eq 
4.9 and for Eq 4.15, respectively. 
diffusion coefficient of the ith species 
diffusion coefficient of free capric acid or of caprate ion 
diffusion coefficient of capric acid»HPB complex or of the 
caprate ion«HPB complex 
effective diffusion coefficient 
fraction of the free capric acid species 
sum of the fractions of the capric acid and the caprate ion 
species 

































capric acid»2-hydroxypropyl-(3-cyclodextrin complex 
caprate ion»2-hydroxypropyl-|3-cyclodextrin complex 




flux into blood 
flux at position X 
actual flux of the permeant 
constant surface concentration of permeant at the tip, lateral 
surface, and crypt of the villi. 
A - + HPB association rate constant, lxlO6 mM'V1 
A~«HPB dissociation rate constant, 4xl05 s"1 
HA + HPB association rate constant, 7.5xl06 mM'V1 
HA»HPB dissociation rate constant, lxlO6 s"1 
caprate ion»HPB binding constant 
HA»HPB binding constant 
length of the ileal segment 
some fraction greater than zero 
total permeability coefficient 
intrinsic membrane permeability coefficient 
Pi as determined from the FSM 
Pi as determined from the VM 
the permeability coefficient determined by appearance into 
blood 
P x,b is the adjusted Px,b that gives P'T,b = P T,e 
Px,e the permeability coefficient determined by the disappearance 
from the lumen 
P'r.e is the adjusted P-r,e that gives P'T,b = P'-r.e 
PABL the ABL permeability coefficient in the absence of a carrier 
P^L ABL permeability coefficient in the presence of a carrier 
Pm effective membrane permeability coefficient 
Q steady-state intestinal perfusate flow rate 
r inside radius of the intestinal segment 
ri villus radius 
r2 radius of the villus and associated intervillus space 
R rate of formation of caprate or the disappearance rate of the 
caprate«HPB complex 
PWM/FSM surface area ratio of the VM to the FSM 
VM villus model 
x position in the lumen (0-1) 
ApH pH gradient 
V the standard del (nabla) operator for cylindrical coordinates 
P buffer capacity 
3Q / 3t slope of cumulative amount vs. time (permeant flux) 
cp the angle in 3D cylindrical coordinates 
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CHAPTER 5 
EXPLORATORY STUDY OF THE ROLE OF CYCLODEXTRINS IN PRESENTING 
CHEMICAL ENHANCERS TO THE SURFACE OF THE RAT 
ILEUM USING THE IN SITU SINGLE PASS 
PERFUSION TECHNIQUE 
5.1 Introduction 
Effective gastrointestinal absorption of highly polar molecules is frequently 
limited by poor intestinal membrane permeability. Because high solubility, low 
permeability (BCS class III) molecules generally have low bioavailability, oral dosing 
formulations of such molecules are frequently not only inefficient, but generally have 
much higher inter- and intrasubject variability.1"3 Recent efforts to improve intestinal 
membrane permeability, and therefore bioavailability, of BCS class III compounds have 
included, among other approaches, the use of membrane permeation-enhancing 
excipients. Compounds that have been studied for their membrane permeation-enhancing 
effects include ionic and non-ionic surfactants,4"13 bile salts,13"24 fatty acids, 5"3 
glycerides,34"40 and others.4"7,41"43 Intestinal membrane permeation enhancers consist of a 
wide range of molecules with a variety of structures and mechanisms of action. Aungst 
et al.44 believe that the three most important criteria for evaluating permeation enhancers 
are (1) how effective the permeation enhancer is for the drug of interest, (2) the potential 
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to cause toxicity, and (3) the mechanisms by which absorption is enhanced. Frequently, 
the toxicity of the enhancers themselves is the limiting factor in successful application of 
the permeation enhancer.6'45'46 The application of materials or methods that would limit 
enhancer toxicity and/or improve the enhancer's effectiveness would certainly improve 
the formulation characteristics and increase the likelihood that the formulation could 
become a marketable product. The present author proposes that the inclusion of 
cyclodextrin carrier molecules in enhancer formulations may provide a means of 
reducing the toxicity and increasing the effectiveness of the permeation enhancer. This 
chapter presents exploratory studies examining the hypothesis that including 
cyclodextrins in permeation-enhancing solutions for delivering BCS class III molecules 
can improve the characteristics of the system. Sulfobutyl ether-P-cyclodextrin (SBE), 
hydroxypropyl-P-cyclodextrin (HPB), and hydroxypropyl-y-cyclodextrin (HPG) will be 
used to represent model cyclodextrin carriers; chenodeoxycholic acid (CDC), a typical 
un-conjugated bile acid, and capric acid (HA), a typical fatty acid, are the chemical 
enhancers; and mannitol is the surrogate for typical BCS class III drug molecules for the 
present study. We have believed there are at least two possible ways in which 
solubilizing agents/carriers like the cyclodextrins may be able to improve the 
performance of lipophilic enhancers such as CDC and capric acid. Firstly, lipophilic 
enhancers such as CDC and capric acid are absorbed rapidly in the intestinal tract 
because they possess very high values of membrane intrinsic permeability coefficients, 
and their transport would likely be close to being aqueous-boundary-layer-controlled. 
Thus, such compounds would have a relatively short half-life in the intestinal fluids (30 
minutes) and this would limit their time of action as an enhancer in the intestinal tract. 
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Cyclodextrins that possess appropriate binding constant(s) for such enhancers may 
prolong their time of action in the intestinal tract by acting to provide a reservoir for the 
enhancer. In this way a larger total dose of enhancer can be administered, with the 
delivery of that dose to the surface being spread out over a longer period of time. It is 
expected that this behavior could potentially increase the enhancers overall effectiveness 
and utility. The second way in which cyclodextrins may aid in the performance of an 
enhancer is by permitting deeper penetration of the enhancer into the crypts (i.e., the 
space between the villi) of the villus structures. In Chapter 4 of this thesis we have 
already noted based on model calculations that penetration of capric acid into the crypt 
regions increases significantly with increasing HPB concentration (see Fig 4.11). Deeper 
penetration into the crypts is expected to permit more effective utilization of the total 
surface area of the intestinal membrane (due to increasing accessibility). This would 
likely mean having the same enhancer performance but with less membrane damage 
because lower steady-state concentrations would be required in the relevant 
microenvironments to obtain the same overall flux of the molecule of interest. 
Alternatively, this could mean having greater enhancer performance at the same steady-
state enhancer concentrations in the villus tip environment. The combination of 
increased half-life and increased surface area accessibility of the enhancing agent due to 
cyclodextrin are hypothesized to provide synergistically beneficial effects on the 
presentation of the enhancing molecule to the surface, with the expectation of increased 
bioavailability of the BCS class III permeant at equal or less enhancer toxicity. The 
purpose of the present study was to experimentally explore several combinations of the 
above mentioned cyclodextrins and enhancers, to interpret the results employing the 
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physical model approach, and to assess the possibilities of this approach in formulation 
development of enhancer systems. 
5.2 Overview 
In order for the reader to more fully understand the author's approach and the 
evolution of thought that went into the design of the experiments presented in this study, 
we present here a chronology of research to date. This study occurred in parallel with the 
studies presented in Chapter 3 and Chapter 4. As such, the physical models developed in 
the previous chapters were not available at the time these studies were designed and 
carried out. Accordingly, these experiments should be considered to be exploratory in 
nature, designed to seek out appropriate enhancer-carrier combinations and 
concentrations that would be suitable for future more systematic, quantitative studies. 
Near the end of the experimental portions of the present study, the physical model results 
presented in Chapter 3 and Chapter 4 were completed and became available to aid in the 
interpretation of the experimental mannitol transport enhancement experiments. 
Mannitol, a compound that is transported across the rat intestinal membrane via 
the paracellular route, was selected to be the permeant in the present study. The mannitol 
flux enhancement range-finding experiments in this study were designed with the 
approach of combining a cyclodextrin carrier with a permeation enhancer to find an 
enhancer-carrier combination that would be effective at enhancing mannitol flux in rat 
ileum. The three cyclodextrin carriers chosen for this study are 1) sulfobutyl ether-[3-
cyclodextrin (SBE), 2) hydroxypropyl-P-cyclodextrin (HPB), and 3) hydroxypropyl-y-
cyclodextrin (HPG). These three carriers were chosen because they have been shown by 
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others as likely not to cause rat intestinal membrane damage.47"49 It was important for the 
present study that the carrier would not damage the membrane so that the chemical 
enhancers used would be permitted to demonstrate their effect on mannitol transport 
without the results being compromised by membrane alteration/damage due to the carrier 
itself. The two enhancers chosen for this investigation, chenodeoxycholic acid (CDC) 
and capric acid (HA), were chosen because they had been previously studied by others as 
permeation enhancers for class III compounds. Additionally, because these enhancers are 
naturally occurring, they may have potential for future biological applications. The first 
combination studied was the CDC/SBE system. The second combination, selected based 
upon the findings with the CDC/SBE system, was the HA/HPB system. The third 
combination studied was the HA/HPG system, its selection based on the results of both 
the SBE/CDC and the HA/HPB studies. 
As will be seen, the ability to utilize the physical model results to interpret the 
experimental results of these enhancer-carrier systems greatly aided in understanding the 
mechanistic aspect of the influence of carriers in the presentation of the enhancers to the 
intestinal surface. The complexity of the enhancer-carrier systems necessitated the use of 
an appropriate physical model to properly interpret the physical meaning of the 
experimental results. 
5.3 Materials and Methods 
5.3.1 Chemicals and reagents 
For the in situ single pass perfusion system, the phosphate buffer solution 
consisted of 57 mM NaHiPCv^O in distilled water. The pH was adjusted to 7.4 with 
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NaOH and the final osmolality was adjusted to 300 mOsm/Kg using Na2S04. Capric 
acid, chenodeoxycolic acid, mannitol, and hydroxypropyl-y-cyclodextrin were obtained 
from Sigma-Aldrich (St. Louis, MO). Sulfobutyl ether-P-cyclodextrin (Trade name 
Captisol) was obtained from CyDex Inc. (Lenexa, Kansas), and hydroxypropyl-pV 
cyclodextrin (Trade name Kleptose HPB) was obtained by a generous gift from Roquette 
America (Keokuk, IA). [14C]Mannitol, [14C]capric acid, and [14C]chenodeoxycholic acid 
were purchased from Moravek Biochemicals Inc. (Brea, CA). The purity of the 
radioisotopes was checked using high pressure liquid chromatography and found to be 
>97% pure. Solvable tissue solubilizer and Ultima Gold scintillation cocktail were 
obtained from PerkinElmer (Boston, MA). Other chemicals were >98% pure. 
5.3.2 Intestinal and mesenteric cannulation 
The procedures used for the single pass perfusion experiments follow the 
procedures used by Tsutsumi et al.50 with some modifications. Male Sprague-Dawley 
rats weighing 300-400 g for intestinal perfusion, or retired breeders for blood donation, 
were obtained from Charles River (Wilmington, MA) and were used under the approval 
of the Institutional Animal Care and Use Committee at the University of Utah. Rats had 
free access to food and water prior to the experiment. Details of the techniques involved 
in the intestinal cannulation, the mesenteric vein cannulation, and blood replacement 
from donor rats are described in detail in Chapter 4 of this thesis. 
5.3.3 Intestinal perfusion 
Perfusion of the solution through the intestinal segment was carried out at 0.2 
ml/min. The perfusate and mesenteric venous blood samples were collected at 10 minute 
158 
intervals. Typical blood flow rates, perfusion outflow rates, and assay procedures were 
the same as those described in Chapter 4. Flux (J) and permeability coefficient (PT) were 
determined using the employing the same methods described in Chapter 4. 
5.3.3.1 CDC/SBE system 
CDC/SBE solutions were prepared using 57 mM NaHaPCVHiO and either 0 or 
7.5 mM SBE. To this was added 0, 1.5, 2.5, 3, 5, 7.5, 10, 12.5, 13.75, or 15 mM cold 
CDC. The pH was then adjusted to 7.4 using NaOH and the osmotic pressure was 
adjusted to 300 +10 Osm/Kg using Na2S04. For mannitol permeability coefficient 
studies, 1-2 pCi/ml [14C]mannitol and 0.05 mM cold mannitol were added to the solution, 
or for the CDC flux determination, 0.2-0.6 joCi/ml [14C]CDC was added to the solution. 
5.3.3.2 HA/HPB solution preparation 
HA/HPB solutions were prepared using 57 mM NaH2P04-H20 and either 0 or 30 
mM HPB. To this was added 0, 2, 10, 12, 15, 20, 30, 35, 40, or 50 mM cold capric acid. 
The pH was then adjusted to 7.4 using NaOH and the osmotic pressure was adjusted to 
300 ±10 Osm/Kg using Na2S04. For mannitol permeability coefficient studies, 1-2 jiCi 
[14C]mannitol and 0.05 mM cold mannitol were added to the system, or for the capric 
acid flux determination, 0.2-0.6 |iCi [14C]capric acid was added to the system. 
5.3.3.3 HA/HPG solution preparation 
HA/HPG solutions were prepared using 57 mM NaH2P04-H20 and either 0 or 30 
mM HPG. To this was added 0, 2, 10, 12, 15, 20, 30, 35, 40, or 50 mM cold capric acid. 
The pH was then adjusted to 7.4 using NaOH and the osmotic pressure was adjusted to 
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300 ±10 Osm/Kg using Na2SC>4. For mannitol permeability coefficient studies, 1-2 
|0.Ci/ml [14C]mannitol and 0.05 mM cold mannitol were added to the system, or for the 
capric acid flux determination, 0.2-0.6 (xCi/ml [14C]capric acid was added to the system. 
5.3.3.4 Villus model (VM) simulations 
Finite-element simulations of permeant diffusion across the ABL and into the 
inter-villus space with drug absorption into a sink at the villus surface were performed 
with computer software FEMLAB (v3.0a, Comsol, Inc. Burlington, MA). The steady 
state diffusion analysis and 2D axial symmetry were used to model permeant absorption 
across the various sites of a single villus in the rat ileum. The idealized villus structure 
was based on previous work by Winne51, and the model parameters were obtained from 
Oliver et al.52 The villus model (VM) simulations were performed in the same manner 
and with the same parameters as in Chapter 4. 
5.4 Results and Discussion 
Because of the exploratory, range-finding nature of the present studies, many of 
the conditions represent only n=l experiments. For those cases where multiple 
experiments were performed, error bars represent the standard deviation of those 
experiments. The experimental results for all enhancer-cyclodextrin systems are listed in 
Tables 5.1 and 5.2. 
5.4.1 Enhancement of mannitol transport in the CDC/SBE system 
SBE was chosen as a carrier to be investigated because it has been suggested47" 
49,53-55
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damage. The seven negative charges (on average) of SBE were expected to help prevent 
lipid extraction from the surface of the ileal membrane. The dissociation of SBE in 
solution is demonstrated as follows. 
Na7SBE—^->7Na+ +SBE"7 
Although the poly-anionic nature of SBE was expected to help prevent any significant 
membrane damage, the associated sodium ions contribute significantly to the overall 
osmolarity of the solution, which limits the SBE concentration that can be studied in iso-
osmotic buffer solutions. CDC was chosen as an enhancer because it was previously 
shown to enhance mannitol transport in rat ileum without serious membrane damage for 
lumen CDC concentrations up to at least 12 mM.24 It should be noted that the critical 
micelle concentration (CMC) for CDC is approximately 2.5 mM. SBE/CDC solutions 
with free concentrations of CDC above 2.5 mM would be a mixture of free monomeric 
CDC, micellar CDC, and/or the CDC»SBE complex, this increasing the complexity of 
the system. 
The results of the mannitol transport studies as a function of CDC concentration 
for the CDC alone solution and the CDC plus 7.5 mM SBE solution are shown in Fig 5.1. 
The baseline mannitol transport rate was determined to be 7.3xl0"7 cm/s. In the presence 
of 7.5 mM SBE, the mannitol transport rate was determined to be 6.3xl0"7, which was 
within experimental error of the baseline mannitol alone transport rate (see Table 5.1). 
These results support the conclusions of others that SBE does not cause membrane 
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Fig 5.1 Mannitol permeability coefficients (PT) for the rat ileum as a function of 
total sodium chenodeoxycholate (CDC) concentration in the presence and absence 
of 7.5 mM sulfobutyl ether-P-cyclodextrin (SBE). 
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demonstrated mannitol does not bind significantly with HPB cyclodextrin (see Chapter 
3). All of this information taken together support the assumption that the mannitol 
enhancement observed from the various CDC/SBE solutions is a result of the enhancer 
action of CDC and not from any kind of direct SBE involvement in the mannitol 
transport across the rat ileum. 
With respect to the enhancement of mannitol transport by CDC, it can be seen in 
Fig 5.1 that the presence of 7.5 mM SBE in the solution has resulted in the need to have a 
significantly higher concentration of CDC to achieve enhancement of mannitol transport 
across the rat ileum. Although SBE was expected to reduce the activity of CDC in 
solution due to the formation of the CDC» SBE complex, and therefore a greater 
concentration of total CDC in solution would be required to obtain a given mannitol 
enhancement factor, it was initially hoped that some degree of significant mannitol 
enhancement could be achieved using CDC concentrations at or below the SBE 
concentration of 7.5 mM. It was anticipated that the carrier effect of SBE would reduce 
the concentration gradient of CDC across the aqueous boundary layer (ABL) to some 
extent and this would partially offset the negative effect of decreased CDC activity (as 
observed with capric acid in the presence of HPB in Chapter 3 and Chapter 4). That 10 
mM CDC in the presence of 7.5 mM SBE did not produce significant mannitol 
enhancement suggests that the binding constant between CDC and SBE was too great to 
allow for an effective enhancer concentration at the surface of the membrane. 
Experiments involving the transport of CDC across a perm-selective membrane 
determined that the CDC« SBE binding constant was approximately 30 mM"1 (data not 
shown). This binding constant was much higher than anticipated and was believed to be 
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the reason CDC did not significantly enhance mannitol transport in the presence of 7.5 
mM SBE for conditions below 12.5 mM CDC. As can be seen in Fig 5.1, significant 
mannitol enhancement did not occur until the CDC concentration exceeds the SBE 
concentration by 5 mM. Furthermore, because of the high CDC* SBE binding constant, 
it was suspected that the observed mannitol enhancement at the 12.5 mM and higher 
CDC concentrations in the presence of 7.5 mM SBE was induced by the CDC in excess 
of the CDC needed to form a one-to-one complex with all of the SBE present rather than 
by any contribution involving SBE as a carrier. Insight into this can be obtained from Fig 
5.2, which presents mannitol enhancement as a function of the lumen concentration of 
free (i.e., uncomplexed) CDC. Based on this plot of the data, mannitol enhancement by 
CDC appears to be merely a function of free CDC concentration in the lumen, 
demonstrating that SBE offered no significant improvement of mannitol enhancement 
over the CDC alone system. Based on this interpretation of the data, it was believed that 
the CDC transport and the enhancing effects of CDC on the mannitol transport rate were 
governed primarily by the excess free CDC, and that the CDC»SBE complex was not 
contributing significantly to the presentation of CDC to the surface for mannitol 
enhancement. Fig 5.3 presents the mannitol permeability coefficient as a function of 
CDC flux. As can be seen, the CDC/SBE results are essentially superposed with the 
CDC alone results. These results were to be expected if one assumed that a flat 
membrane adequately represented the surface of the rat ileum (FSM of Chapter 4). It has 
been shown, however, that when taking the villus model (VM) into consideration, it was 
expected that the CDC alone and the CDC/SBE results presented in Fig 5.3 may not 
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Fig 5.2 Mannitol permeability coefficients (PT) for the rat ileum as a function of free 
sodium chenodeoxycholate (CDC) concentration in the lumen in the presence and 
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Fig 5.3 Mannitol permeability coefficients (Pj) as a function of sodium 
chenodeoxycholate (CDC) flux across the rat ileum in the presence and absence of 7.5 
mM sulfobutyl ether-P-cyclodextrin (SBE). 
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4). In light of the villus model, the fact that the data points on Fig 5.3 for CDC alone and 
those for CDC/SBE are essentially superposed suggest that CDC is utilizing essentially 
the same amount of surface area for transport in both systems. Fig 5.4 demonstrates that 
the CDC flux vs. free CDC lumen concentration (bulk activity) data for the two solutions 
being compared again superpose in the data plots. These results suggest that including 
7.5 mM SBE in a formulation does not increase the CDC flux for constant activity 
comparisons. This interpretation of the data presented in Fig 5.4 is consistent with the 
interpretation of the data presented in Figs 5.1-5.3: that the very high binding constant of 
the CDC»SBE complex prevented effective concentrations of the enhancer from being 
presented to the membrane surface for 7.5 mM SBE systems with CDC concentrations 
below 12.5 mM. The mannitol enhancement observed for the 12.5, 13.75, and 15 mM 
CDC conditions in the presence of 7.5 mM SBE has likely resulted primarily from the 
excess CDC in the solution rather than from any advantageous effect of including SBE in 
the solution. In theory, one could foresee using equal concentrations of CDC and SBE 
that were high enough to present effective enhancer concentrations at the surface of the 
ileum, but such concentrations of CDC and SBE required to achieve this result are likely 
to be very high. Due to the significant influence the poly-anionic SBE on the osmolarity 
of the solution, practical constraints prevent us from increasing the concentration much 
higher than 7.5 mM without sustaining detrimental consequences to the buffer capacity 
and/or the isotonicity of the system. Accordingly, at this point in the research, an 
enhancer-cyclodextrin system was sought that did not have the concentration constraints 
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Fig 5.4 Sodium chenodeoxycholate (CDC) flux across the rat ileum as a function of 
free CDC concentration in the lumen in the presence and absence of 7.5 mM 
sulfobutyl ether-P-cyclodextrin (SBE). 
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With respect to interpreting the CDC/SBE system with the VM, unfortunately a 
reliable intrinsic permeability coefficient value for CDC was not attainable because the 
actively transported CDC was ABL controlled and, therefore, not sensitive to an accurate 
determination of the CDC intrinsic permeability coefficient from membrane transport 
experiments. Unfortunately, therefore, the VM discussion in Section 5.4.4 are limited to 
the HA/HPB and the HA/HPG systems. 
5.4.2 HA/HPB enhancer-carrier system for 
the enhancement of mannitol transport 
The second cyclodextrin carrier selected for enhancer-carrier studies was 
hydroxypropyl-p-cyclodextrin (HPB). This carrier was selected because it has been 
demonstrated by others not likely to cause membrane damage47"49 and because solutions 
containing the neutral but highly polar HPB would be less osmotically constrained than 
the poly-anionic SBE carrier. Capric acid (HA) was selected as the second enhancer to 
study because we anticipated that HA*HPB would have a lower binding constant than the 
SBE»CDC complex. Preliminary binding constant experiments using the perm-selective 
membrane transport method confirmed that the HA»HPB binding constant was 
approximately 10 times lower than the SBE«CDC binding constant (this was thought to 
be encouraging). The CMC of capric acid was experimentally determined using the 
perm-selective membrane transport experiments56 and found to be approximately 35 mM 
(data not shown), which allowed for significantly high free capric acid concentrations in 
buffer without forming micelles. Additionally, the capric acid half-life in the rat ileum 
for the HA/HPB system was determined to be 2.9 times longer than capric acid alone 
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case (see Table 5.3). Based on the characteristics of capric acid and HPB, we anticipated 
more interesting results with this enhancer-carrier system than with the CDC/SBE 
system. The mannitol permeability coefficients as a function of capric acid concentration 
in the presence and absence of 30 mM HPB are presented in Fig 5.5. As can be seen, 
capric acid alone enhanced mannitol transport for concentrations above 10 mM capric 
acid. For the mannitol transport enhancement experiments involving 30 mM HPB, 
significant enhancement did not occur with up to 40 mM capric acid. Drawing your 
attention to the 30 mM capric acid plus 30 mM HPB data point in Fig 5.5, there was 
evidence of some mannitol transport enhancement for this situation. This experiment 
was repeated n=4, with two experiments yielding baseline mannitol transport results and 
two experiments yielding enhanced mannitol transport results (as demonstrated by the 
large error bars). This leaves the interpretation of the results for this particular situation 
somewhat inconclusive; however the lack of enhancement for the higher capric acid 
concentrations in the presence of 30 mM HPB suggests that the two experiments 
resulting in elevated mannitol transport may have been outliers rather than representative 
experiments. Capric acid concentrations higher than 30 mM HPB were not studied. This 
decision not to examine higher capric acid concentrations in the presence of 30 mM HPB 
was unfortunate as can be understood from the discussion to follow. Fig 5.6 presents an 
examination of the relationship of mannitol permeability coefficients to capric acid flux. 
Unlike the CDC/SBE system (see Fig 5.3) the results with the HA/HPB system do not 
superpose. Based on the results in Chapters 3 and 4, in the case of a smooth surface 
(FSM), the capric acid flux should be proportional to the capric acid species surface 
concentration; and also because it is reasonable to expect that enhancer action may be a 
Table 5.3 Relative half-life in rat ileum for capric acid (HA) 
alone, in the presence of 30 mM hydroxypropyl-P-cyclodextrin 
(HPB) and in the presence of 30 mM hydroxypropyl-y-
cyclodextrin (HPG). The relative half-life was determined by 
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Fig 5.5 Mannitol permeability coefficients (PT) for the rat ileum as a function of total 
capric acid (HA) concentration for capric acid alone and capric acid plus 30 mM 
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Fig 5.6 Mannitol permeability coefficients (PT) for the rat ileum as a function of 
capric acid (HA) flux for capric acid alone and for capric acid plus 30 mM 
hydroxypropyl-P-cyclodextrin (HPB) or 30 mM hydroxypropyl-y-cyclodextrin 
(HPG). Dashed line for HA + 30 mM HPB is speculation but illustrates a reasonable 
possibility. 
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single valued function of the surface enhancer concentration, it is reasonable to propose 
that superpositioning of the results of Fig 5.3 suggests no significant carrier effect arising 
from the presence of SBE that may give rise to a higher capric acid species surface 
concentration. The HA alone and the HA + 30 mM HPB results (Fig 5.6) however do not 
superpose and the latter data are rightwardly displaced relative to the HA alone data. A 
reasonable explanation for this is the following: As discussed in Chapter 4, for the 
HA/HPB system, there is likely an increased effective area for absorption due to a more 
extensive penetration of HA into the villus crypts that can permit yielding the same 
mannitol PT value as for HA alone but at a higher capric acid flux and at a lower average 
surface capric acid species concentration. 
Fig 5.7 presents the capric acid flux as a function of free capric acid concentration 
in the lumen. This plot demonstrates clearly that HPB provides significantly greater 
capric acid flux than the capric acid alone solutions for a given lumen activity of free 
capric acid. This was in contrast to the CDC/SBE behavior seen in Fig 5.4 where the 
CDC/SBE data and the CDC alone data essentially superposed. The increased capric 
acid flux in the presence of HPB is clear from the data presented in Fig 5.7; however, the 
mechanism for the increased flux remained unclear. As will be discussed later, using the 
villus model (VM) reveals that HPB significantly reduced the concentration gradient of 
capric acid activity across the ABL and allowed the capric acid to utilize up to four-fold 
more surface area for absorption than in the absence of HPB. 
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Fig 5.7 Capric acid (HA) flux across the rat ileum as a function of free capric acid 
concentration for capric acid alone and for capric acid plus 30 mM hydroxypropyl-P-
cyclodextrin (HPB) or 30 mM hydroxypropyl-y-cyclodextrin (HPG). 
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5.4.3 HA/HPG enhancer-carrier system for 
the enhancement of mannitol transport 
Based on the initial interpretation of the results of the HA/HPB studies, it was 
thought that a still smaller capric acid-cyclodextrin binding constant was required for a 
system that would yield mannitol enhancement with more reasonable concentrations of 
enhancer and carrier. HPG was investigated because it was expected to bind more 
weakly to capric acid due to the larger cavity size of HPG as compared to HPB. Perm-
selective membrane transport experiments56 determined that binding constant between 
capric acid and HPG was 0.5 mM"1. Accordingly, we expected the highest concentration 
of free enhancer and, therefore, the highest probability of attaining mannitol enhancement 
at reasonable concentrations of capric acid and HPG. Additionally, the capric acid half-
life in the rat ileum for the HA/HPG system was determined to be 2.4 times longer than 
capric acid alone case (see Table 5.3). The mannitol and capric acid transport data for the 
HA/HPG system are presented in Figs 5.5-5.7 along side the capric acid alone data and 
the HA/HPB data. 
In Fig 5.5 we see that mannitol transport enhancement occurred in the presence of 
30 mM HPG for capric acid concentrations at and above 30 mM, with higher capric acid 
concentrations resulting in greater mannitol permeability coefficients. While most of the 
HA/HPG conditions were composed of a higher concentration of total capric acid than of 
HPG, the behavior of the HA/HPG system (as was the HA/HPB system), is clearly 
different from the CDC/SBE system, which involved very strong CDOSBE complexes 
(Section 5.4.1.) For the CDC/SBE case, CDC transport and mannitol enhancement 
behaved as if the bound CDC did not contribute at all to the CDC flux or the mannitol 
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enhancement, and that the CDC/SBE solutions appeared to behave the same as CDC 
alone at the same free CDC concentration in the lumen. The relationship between the 
mannitol permeability coefficient and capric acid flux for the HA/HPG solutions, on the 
other hand, differed with the CDC/SBE system but was similar to the HA/HPB system 
(compare Fig 5.3 with Fig 5.6; Compare Fig 5.4 with Fig 5.7). 
Fig 5.6 demonstrates that the capric acid plus HPG solutions require a higher 
capric acid flux than capric acid alone before mannitol enhancement is observed. It 
appears, however, that when a critical capric acid flux is reached, the mannitol 
permeability coefficient can increase rapidly. This behavior would be difficult to explain 
assuming a flat surface membrane (the FSM model of Chapter 4). With the villus 
structure in mind however as in the case for the HA/HPB system, a reasonable hypothesis 
explaining the Fig 5.6 results may be presented as follows. As demonstrated in Chapter 
4, capric acid is absorbed almost exclusively at the tips for capric acid alone. This 
suggests that, in this case, the only region of the villi that can be enhanced is the region 
near the villus tips. In the presence of HPG, however, capric acid may access regions of 
the villus crypts that capric acid alone may not. Higher capric acid flux may, therefore, 
be reached without attaining significant mannitol flux enhancement at any point along the 
surface sites of the villi. This can mean, also, that when high enough capric acid 
concentrations are used in HA/HPG solutions, mannitol transport enhancement may 
occur over a greater villus surface area. 
The significantly greater capric acid flux for the HA/HPG solutions as compared 
to capric acid alone at equal free capric acid concentration in the lumen (Fig 5.7) deserves 
a comment. It was initially suspected that was due only to the carrier effect across the 
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ABL (as demonstrated in Chapter 3); however, the VM suggests that this increased capric 
acid flux is caused by a both the ABL carrier effect and the increased surface area utilized 
for absorption due to deeper penetration of capric acid into the villus crypts. As with the 
HA/HPB system, the physical model is required to distinguish the relative importance of 
the ABL carrier effect and the increased surface area effect in accounting for the overall 
increase in capric acid flux for the cyclodextrin-containing systems as compared to the 
capric acid alone case. 
Taken as a whole, Figs 5.1-5.7 suggest that cyclodextrin carriers may provide the 
means by which the concentration gradient of enhancers across the ABL can be reduced 
and more of the membrane surface can be effectively enhanced and utilized for 
absorption. The net result of these effects may include increased duration of action for 
the enhancer and reduced toxicity caused by the enhancer, (as a consequence of the 
greater accessibility of the total surface area resulting in lower average 
microenvironmental concentration of the enhancer to achieve the same net enhancement) 
as well as a potentially higher maximum flux of the target permeant (mannitol in this 
case). In order to better understand the relationship that exists between the parameters 
that govern the presentation of chemical enhancers to the membrane surface by 
cyclodextrin carriers, the VM is required. Accordingly, the capric acid experimental data 
from this study is interpreted in the following discussion using the VM. 
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5.4.4 Insights obtained from examining the capric 
acid experimental results using the villus model 
The villus model (VM) described in Chapter 4 may be used to obtain information 
on increased effective surface area for capric acid absorption in the presence of the 
carriers HPB and HPG. Accessibility represents the fraction of available surface area 
utilized for absorption as defined in Chapter 4. Table 5.4 presents the accessibility of 
capric acid for several HPB and HPG solutions relative to trace capric acid alone 
calculated using the VM. These accessibility values were calculated using a constant 
intrinsic membrane permeability coefficient (PJ.VM) value for capric acid based on 
experimental results described in Chapter 4. This assumes that capric acid does not 
enhance its own flux. As can be seen, HPB increases the capric acid accessibility to a 
somewhat greater extent than HPG. For both cases, the accessibility decreases with 
increasing capric acid concentration due to the non-linear binding behavior (i.e. partial 
saturation effects) of the enhancer and cyclodextrin for the higher capric acid 
concentration conditions. For both cases, the greater penetration of capric acid into the 
villus crypts provides opportunities for enhancing mannitol transport across a greater 
fraction of the total intestinal surface area. Fig 5.8 presents results of VM calculations 
showing the concentration profiles of free capric acid across the ABL and within the 
intervillus space for the three cases where the capric acid activity is normalized to be 
equal at the villus tips. These plots suggest that, when comparing the three cases, for a 
given free capric acid concentration at the villus tips (and therefore, presumably, at a 
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Fig 5.8 Free total capric acid (HA) concentration profiles for the three cases: 8 mM HA 
alone; 30 mM HA + 30 mM HPG; 44mM HA + 30 mM HPB. The capric acid 
concentrations in the ileum lumen were chosen so that, for all three cases, the free caprate 
concentration at the villus tips would be equal to that for the 30 mM HA + 30 mM HPG 
case. The vertical line represents the location of the villus tips. 
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available surface area and thus provide the greatest potential increase in mannitol 
bioavailability. 
It is instructive at this point to examine how well the results of Table 5.4 are 
consistent with the actual experimental data of Fig 5.6. We shall take three examples. 1) 
An HA/HPB case. First, take data point 40 mM HA/30 mM HPB, where the capric acid 
flux is 7.2 x 10"8 and the mannitol PT value is 1.6 x 10"6 (see Table 5.2). The increased 
accessibility for this case relative to capric acid alone is 3.0 (Table 5.4). Therefore the 
Q O 
predicted capric acid flux for capric acid alone would be 7.2 x 10" / 3.0= 2.4 x 10" . As 
can be seen in Fig 5.9, this prediction is in very good agreement with the experimental 
value and supports the validity of the hypothesis. This is a good example because we 
have selected a data point for which the mannitol enhancement is quite modest (around a 
factor of 2). 2) An HA/HPG case. Similar to the calculation for the HA/HPB case we 
may select a data point from the HA/HPG data set. It seems that the data point with the 
least mannitol enhancement but clearly higher than baseline mannitol Px value is the case 
of 30 mM HA/30 mM HPG, where the capric acid flux is 6.7 x 10"8 and the mannitol PT 
value is 3.7 x 10"6 (see Table 5.2). The increased accessibility for this case relative to 
capric acid alone is 2.0 (Table 5.4). Therefore the predicted capric acid flux for the 
Q 
capric acid alone for this case would be 3.3 x 10" (see Fig 5.9). The predicted value is 
around 73% of the experimental capric acid flux value (interpolated from a smooth 
curve) for capric acid alone. In light of the large experimental data scatter, the agreement 
should be considered satisfactory. Also, the experimental Py for mannitol (-3.7 x 10"6) is 
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capric acid flux for 
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0.0E+00 
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Fig 5.9 Mannitol permeability coefficients (Pj) for the rat ileum as a function of capric 
acid (HA) flux for capric acid alone and for capric acid plus 30 mM hydroxypropyl-p-
cyclodextrin (HPB) or 30 mM hydroxypropyl-y-cyclodextrin (HPG). 
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Likely, this will impact somewhat on the assumption that the baseline Pi values of capric 
acid may be used in the calculations, while this consideration would be less important for 
HA/30 mM HPG solution have similar free concentrations of capric acid at the villus tips 
(0.42 mM and 0.43 mM, respectively) according to VM calculations. Their relative HA 
flux and mannitol enhancement factors are given in Table 5.5. A comparison of the 
experimental results demonstrates that the solution containing HPG provided a 2.5-fold 
greater mannitol enhancement than the capric acid alone solution for the given tip 
concentration. This comparison illustrates the potential for cyclodextrin carriers to 
provide greater enhancement for a given free tip concentration of enhancer (a measure of 
the membrane toxicity). An examination of these three examples demonstrates that, 
although these studies were exploratory in nature, the experimental results are found to be 
quantitatively consistent with the VM. 
5.5 Implications 
This range-finding study and the interpretation of the experimental results using 
the VM provide significant insight into the optimum characteristics for ideal 
combinations of permeation enhancers and cyclodextrin carriers for improving the 
bioavailability of BCS class III compounds. The VM clearly demonstrates that 
enhancer/cyclodextrin combinations with higher binding constants provide increased 
enhancer accessibility to the villus surface (Table 5.4) and increased duration of action 
due to an increased half-life (Table 5.3). The increased binding constant, however, also 
decreases F u at the surface. Therefore, an ideal enhancer/cyclodextrin combination would 
consist of a cyclodextrin molecule with a high enough enhancer binding constant to 
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Table 5.5 A comparison of capric acid (HA) flux and mannitol enhancement factor 
for two conditions with similar capric acid (HA) tip concentrations. 
[HA]free,tip HA flux Enhancement 
Condition (mM) (moles/min/cm2) factor 
lOmMHA 0.42 4.3 x10"8 3.6 
35 mM HA + 30 mM HPG 0.43 7.7 x 10"8 9.0 
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achieve near-maximum accessibility and provide an optimum enhancer half-life in the 
lumen, combined with an enhancer that was potent enough to cause enhancement at very 
low surface concentrations without causing an unacceptable level of toxicity at 
therapeutic concentrations. As long as the enhancer is potent enough to cause membrane 
permeation enhancement in the presence of the cyclodextrin at practical concentrations, 
the formulation could be fine-tuned to provide optimum surface free concentrations of the 
enhancer and appropriate duration of action by simply adjusting the enhancer and/or 
carrier concentrations accordingly. The increased half-life and decreased concentration 
gradient resulting from including cyclodextrins in enhancer formulations is expected to 
facilitate safer and more effective enhancer delivery by presenting a greater intestinal 
surface area with a more narrow range of enhancer concentrations for a longer duration. 
These effects are expected to increase the likelihood that safe and effective permeation-
enhancing formulations may someday be developed for commercial application. 
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CHAPTER 6 
SUMMARY 
The increasing number of therapeutic chemical entities that are not currently 
capable of effective oral delivery due to poor bioavailability in the intestinal tract due to 
poor solubility and/or poor permeability has fostered the need to develop formulations 
that can increase the oral bioavailability to acceptable levels. Although the field has 
recently seen significant progress from the standpoint of practical formulation 
development, there has been a great need for progress from the standpoint of gaining a 
quantitative mechanistic understanding of the interplay of key variables involved in the 
formulation development of poor bioavailability drugs. A primary focus of this 
dissertation has been to foster a better understanding of the key variables involved in 
formulations employing cyclodextrin molecules to increase the bioavailability of poorly 
soluble, highly permeable compounds. An additional focus of this dissertation was to 
demonstrate the potential benefits of including a cyclodextrin carrier in permeation 
enhancing formulations to improve the effectiveness and possibly the safety of the 
enhancer. 
A physical model was designed to incorporate the key parameters involved in the 
transport of highly lipophilic molecules in the presence of cyclodextrin. The physical 
model accounted for the cyclodextrin and permeant concentrations, the solution pH, the 
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permeant pKa, the permeant/cyclodextrin binding constant(s), the aqueous boundary 
layer thickness, the diffusion coefficients of the free and cyclodextrin-bound permeant, 
and the intrinsic membrane permeability coefficient. Independent or essentially 
independent experiments were utilized to determine the parameter values involved. 
Capric acid was used as a model permeant and hydroxypropyl-|3-cyclodextrin (HPB) was 
used as a model cyclodextrin carrier to demonstrate the reliability of the model by 
comparing experimental and model-predicted permeability coefficients (PT) for the 
transport of capric acid across a silicone polymer membrane over a range of 100% ABL-
controlled to 100% membrane-controlled conditions. The PT values predicted by the flat 
membrane model (FSM) were in good agreement with the experimental values over the 
entire range of conditions, validating the physical model. Using the FSM, it was 
demonstrated that for constant free lumen concentrations of capric acid (i.e., saturated 
solution), the concentration gradient of free capric acid was reduced with increasing 
concentrations of HPB, resulting in increasing surface free capric acid concentrations and 
capric acid flux with increasing concentrations of HPB. 
As a result of the good agreement of the experimental and model-predicted results 
of the in vitro silicone polymer membrane transport experiments, the (FSM) was applied 
to capric acid transport across rat ileum in the presence of HPB using a single pass 
perfusion technique. As in the silicone polymer membrane transport experiments, the 
model accurately described capric acid flux over a range of HPB concentrations. The 
(FSM) was then extended to account for the villus structure of the ileal membrane, and 
the predicted results were compared to experimental data. As with the FSM, the PT 
values determined using the villus model (VM) were in good agreement with 
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experimental data, and although both models were in good agreement with experimental 
data, the VM provided additional insight that was not available from the FSM. First, the 
VM demonstrated that, when HPB was not present in the luminal solution, capric acid 
was absorbed primarily at the villus tips; in the presence of HPB, capric acid was able to 
penetrate further into the villus crypts, thus utilizing a greater fraction of the available 
surface area of the rat ileum. For the 50 mM HPB case, capric acid was able to utilize 4.5 
times as much surface area as the capric acid alone system. This increased accessibility 
due to HPB, combined with the reduced concentration gradient of free capric acid across 
the ABL, quantitatively demonstrate why HPB is able to increase the bioavailability of 
highly lipophilic molecules. 
The VM also afforded the opportunity to mechanistically examine how the 
cyclodextrins may be able to improve the performance of membrane permeation 
enhancers such as capric acid by better presentation of the enhancer at the membrane 
surface. Three enhancer/cyclodextrin combinations were investigated, and the 
experimental data were analyzed with the VM. It was demonstrated that cyclodextrin 
carriers may increase the effective surface area enhanced by the enhancer, resulting in 
greater overall permeant enhancement for a given concentration of free enhancer at the 
villus tips. 
The implications of these studies and the interpretation of the experimental results 
using the VM provide significant insight into the optimum characteristics for ideal 
combinations of permeation enhancers and cyclodextrin carriers for improving the 
bioavailability of BCS class II and class III compounds. The VM clearly demonstrates 
and quantitatively predicts that cyclodextrins may 1) increase the flux of highly 
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lipophilic compounds, 2) increase the fraction of available surface area utilized for 
absorption/enhancement, 3) increase the enhancer's duration of action, and 4) increase 
the enhancement factor for a given enhancer concentration at the villus tip. This is the 
first time, to our knowledge, that the quantitative modeling of cyclodextrin carrier effects 
and the use of cyclodextrins to more effectively present permeation enhancers to the 
membrane surface have been demonstrated. The VM provides the means by which ideal 
permeant/carrier or enhancer/carrier combinations could be determined in formulation 
development. 
